NO176839B - Ligands and methods for their preparation, metal complexes formed with these ligands, as well as diagnostic composition and X-ray contrast agent comprising the above metal complexes - Google Patents
Ligands and methods for their preparation, metal complexes formed with these ligands, as well as diagnostic composition and X-ray contrast agent comprising the above metal complexes Download PDFInfo
- Publication number
- NO176839B NO176839B NO881567A NO881567A NO176839B NO 176839 B NO176839 B NO 176839B NO 881567 A NO881567 A NO 881567A NO 881567 A NO881567 A NO 881567A NO 176839 B NO176839 B NO 176839B
- Authority
- NO
- Norway
- Prior art keywords
- formula
- complex
- group
- stated
- ppm
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims description 50
- 238000000034 method Methods 0.000 title claims description 9
- 239000002872 contrast media Substances 0.000 title claims description 5
- 239000000203 mixture Substances 0.000 title description 31
- 229910052751 metal Inorganic materials 0.000 title description 6
- 239000002184 metal Substances 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 43
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 18
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 17
- -1 cyclic amine Chemical class 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- 230000005291 magnetic effect Effects 0.000 claims description 8
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 7
- 229910021645 metal ion Inorganic materials 0.000 claims description 7
- 229910021644 lanthanide ion Inorganic materials 0.000 claims description 6
- 229920000768 polyamine Polymers 0.000 claims description 6
- MDYZHYKKBPMPDR-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-9-(hydroxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OCC1CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN1 MDYZHYKKBPMPDR-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 4
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 4
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 2
- 229910052693 Europium Inorganic materials 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 55
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 37
- 239000000047 product Substances 0.000 description 34
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- 239000000377 silicon dioxide Substances 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 238000004809 thin layer chromatography Methods 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 150000001491 aromatic compounds Chemical class 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 229910004298 SiO 2 Inorganic materials 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(III) oxide Inorganic materials [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940106681 chloroacetic acid Drugs 0.000 description 4
- 229910052681 coesite Inorganic materials 0.000 description 4
- 229910052906 cristobalite Inorganic materials 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 4
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 4
- 229940075613 gadolinium oxide Drugs 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 229910052682 stishovite Inorganic materials 0.000 description 4
- 229910052905 tridymite Inorganic materials 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000001636 atomic emission spectroscopy Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CYBRBDXWHPQWHU-UHFFFAOYSA-N 2,6-dimethyl-1,4,7,10-tetrakis-(4-methylphenyl)sulfonyl-1,4,7,10-tetrazacyclododecane Chemical compound CC1CN(S(=O)(=O)C=2C=CC(C)=CC=2)CC(C)N(S(=O)(=O)C=2C=CC(C)=CC=2)CCN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN1S(=O)(=O)C1=CC=C(C)C=C1 CYBRBDXWHPQWHU-UHFFFAOYSA-N 0.000 description 2
- YJCDJROSKJIJMI-UHFFFAOYSA-N 2-[(4-methylphenyl)sulfonyl-[2-[(4-methylphenyl)sulfonyl-[2-(4-methylphenyl)sulfonyloxyethyl]amino]ethyl]amino]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCN(S(=O)(=O)C=1C=CC(C)=CC=1)CCN(S(=O)(=O)C=1C=CC(C)=CC=1)CCOS(=O)(=O)C1=CC=C(C)C=C1 YJCDJROSKJIJMI-UHFFFAOYSA-N 0.000 description 2
- NMRVEKQKYDNYIO-UHFFFAOYSA-N 2-[4,7,10,13-tetrakis(carboxymethyl)-8-methyl-1,4,7,10,13-pentazacyclopentadec-1-yl]acetic acid Chemical compound CC1CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN1CC(O)=O NMRVEKQKYDNYIO-UHFFFAOYSA-N 0.000 description 2
- PTNYVRLOIWSBGQ-UHFFFAOYSA-N 2-hexyl-1,4,7,10-tetrazacyclododecane Chemical compound CCCCCCC1CNCCNCCNCCN1 PTNYVRLOIWSBGQ-UHFFFAOYSA-N 0.000 description 2
- JJGLDZUABHRMDJ-UHFFFAOYSA-N 4-methyl-n-[2-[(4-methylphenyl)sulfonylamino]propyl]benzenesulfonamide Chemical compound C=1C=C(C)C=CC=1S(=O)(=O)NC(C)CNS(=O)(=O)C1=CC=C(C)C=C1 JJGLDZUABHRMDJ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- YPPDKJJBAIDOLA-UHFFFAOYSA-N 1-(2-hydroxyethylamino)octan-2-ol Chemical compound CCCCCCC(O)CNCCO YPPDKJJBAIDOLA-UHFFFAOYSA-N 0.000 description 1
- GTKCLZBVGPBHSG-UHFFFAOYSA-N 2,6-dimethyl-1,4,7,10-tetrazacyclododecane Chemical compound CC1CNCC(C)NCCNCCN1 GTKCLZBVGPBHSG-UHFFFAOYSA-N 0.000 description 1
- VJDZYMIEDBLSDT-UHFFFAOYSA-N 2-[(4-methylphenyl)sulfonyl-[2-(4-methylphenyl)sulfonyloxyethyl]amino]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCN(S(=O)(=O)C=1C=CC(C)=CC=1)CCOS(=O)(=O)C1=CC=C(C)C=C1 VJDZYMIEDBLSDT-UHFFFAOYSA-N 0.000 description 1
- GGKPHYHTHNORAL-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-12-methyl-1,4,7,10,13-pentazacyclopentadec-1-yl]acetic acid Chemical compound CC1CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN1 GGKPHYHTHNORAL-UHFFFAOYSA-N 0.000 description 1
- HSXRCEVTMOWCFI-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-6-methyl-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound CC1CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN1CC(O)=O HSXRCEVTMOWCFI-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- DYRQSXNUQCWPNX-UHFFFAOYSA-N 2-hexyl-1,4,7,10-tetrakis-(4-methylphenyl)sulfonyl-1,4,7,10-tetrazacyclododecane Chemical compound CCCCCCC1CN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN1S(=O)(=O)C1=CC=C(C)C=C1 DYRQSXNUQCWPNX-UHFFFAOYSA-N 0.000 description 1
- NJWSNNWLBMSXQR-UHFFFAOYSA-N 2-hexyloxirane Chemical compound CCCCCCC1CO1 NJWSNNWLBMSXQR-UHFFFAOYSA-N 0.000 description 1
- HPYNHVXTIHSZBE-UHFFFAOYSA-N 2-methyl-1,4,7,10,13-pentakis-(4-methylphenyl)sulfonyl-1,4,7,10,13-pentazacyclopentadecane Chemical compound CC1CN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN1S(=O)(=O)C1=CC=C(C)C=C1 HPYNHVXTIHSZBE-UHFFFAOYSA-N 0.000 description 1
- UFYVFYUCDPIIQM-UHFFFAOYSA-N 2-methyl-1,4,7,10,13-pentazacyclopentadecane Chemical compound CC1CNCCNCCNCCNCCN1 UFYVFYUCDPIIQM-UHFFFAOYSA-N 0.000 description 1
- FQGMWYLNOSINOL-UHFFFAOYSA-N 2-methyl-1,4,7,10-tetrakis-(4-methylphenyl)sulfonyl-1,4,7,10-tetrazacyclododecane Chemical compound CC1CN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN(S(=O)(=O)C=2C=CC(C)=CC=2)CCN1S(=O)(=O)C1=CC=C(C)C=C1 FQGMWYLNOSINOL-UHFFFAOYSA-N 0.000 description 1
- YTCSKODYWQUOKD-UHFFFAOYSA-N 2-methyl-1,4,7,10-tetrazacyclododecane Chemical compound CC1CNCCNCCNCCN1 YTCSKODYWQUOKD-UHFFFAOYSA-N 0.000 description 1
- XQKAYTBBWLDCBB-UHFFFAOYSA-N 3,4-diaminobutanoic acid Chemical compound NCC(N)CC(O)=O XQKAYTBBWLDCBB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- DGLWWXSXFWPANL-UHFFFAOYSA-N 4-methyl-n-[3-[(4-methylphenyl)sulfonyl-[3-[(4-methylphenyl)sulfonylamino]propyl]amino]propyl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCCCN(S(=O)(=O)C=1C=CC(C)=CC=1)CCCNS(=O)(=O)C1=CC=C(C)C=C1 DGLWWXSXFWPANL-UHFFFAOYSA-N 0.000 description 1
- JKTORXLUQLQJCM-UHFFFAOYSA-N 4-phosphonobutylphosphonic acid Chemical compound OP(O)(=O)CCCCP(O)(O)=O JKTORXLUQLQJCM-UHFFFAOYSA-N 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 101100352919 Caenorhabditis elegans ppm-2 gene Proteins 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- YWVLYOLHUZNPRA-UHFFFAOYSA-N S(=O)(=O)(O)O.CC1NCCNCCNC(CNC1)C Chemical compound S(=O)(=O)(O)O.CC1NCCNCCNC(CNC1)C YWVLYOLHUZNPRA-UHFFFAOYSA-N 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical group [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- LHIJANUOQQMGNT-UHFFFAOYSA-N aminoethylethanolamine Chemical class NCCNCCO LHIJANUOQQMGNT-UHFFFAOYSA-N 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- AMEDKBHURXXSQO-UHFFFAOYSA-N azonous acid Chemical class ONO AMEDKBHURXXSQO-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- HRGNJWJNQCHWAS-UHFFFAOYSA-N n,n-bis(2-aminopropyl)-4-methylbenzenesulfonamide Chemical compound CC(N)CN(CC(C)N)S(=O)(=O)C1=CC=C(C)C=C1 HRGNJWJNQCHWAS-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- KPFSGNRRZMYZPH-UHFFFAOYSA-M potassium;2-chloroacetate Chemical compound [K+].[O-]C(=O)CCl KPFSGNRRZMYZPH-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D259/00—Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Paints Or Removers (AREA)
Abstract
Description
Foreliggende oppfinnelse vedrører nye nitrogenholdige cykliske ligander og metallkomplekser dannet ved hjelp av disse ligander, diagnostisk preparat omfattende minst ett av de ovennevnte komplekser for anvendelse i forbindelse med magnetisk resonanspåvisning, samt røntgenkontrastmiddel også omfattende ett eller flere av de ovennevnte komplekser. The present invention relates to new nitrogen-containing cyclic ligands and metal complexes formed with the help of these ligands, a diagnostic preparation comprising at least one of the above-mentioned complexes for use in connection with magnetic resonance detection, as well as an X-ray contrast agent also comprising one or more of the above-mentioned complexes.
Oppfinnelsen vedrører også en fremgangsmåte for fremstilling The invention also relates to a method for production
av ligandene. of the ligands.
Disse og andre trekk ved oppfinnelsen fremgår av patent- These and other features of the invention appear in patent
kravene. the requirements.
Således, vedrører oppfinnelsen en ligand som er kjennetegnet Thus, the invention relates to a ligand which is characterized
ved at den har formel I: in that it has formula I:
hvori in which
Rx representerer et radikal med formel: Rx represents a radical with formula:
hvori in which
R6 velges fra gruppen bestående av C1-C14 alkyl, C1-C4 hydroksyalkyl og en gruppe med formel: R6 is selected from the group consisting of C1-C14 alkyl, C1-C4 hydroxyalkyl and a group of formula:
hvori in which
Rn representerer C1- Ca alkylen, Rn represents the C1-C6 alkylene,
R7 velges fra gruppen bestående av hydrogen, C^-C^ alkyl og CX-C4 hydroksyalkyl, R 7 is selected from the group consisting of hydrogen, C 1 -C 4 alkyl and C 1 -C 4 hydroxyalkyl,
R2, R3 og R4 representerer et radikal med formel: R2, R3 and R4 represent a radical with formula:
n = 1 eller 2, og n = 1 or 2, and
Z representerer en gruppe med formel: Z represents a group with formula:
hvori in which
R10 velges fra gruppen bestående av hydrogen og -CH2-COOH, såvel som saltene derav. R10 is selected from the group consisting of hydrogen and -CH2-COOH, as well as the salts thereof.
Ligandene med formel I fremstilles ved at et polyamin med formel IV: hvori R' 1 representerer et radikal med formel: The ligands of formula I are prepared by a polyamine of formula IV: in which R' 1 represents a radical of formula:
hvori in which
R'6 er valgt fra gruppen bestående av Cx- C14 alkyl, Cx-C4 hydroksylalkyl og en gruppe med formel: R'6 is selected from the group consisting of Cx-C14 alkyl, Cx-C4 hydroxylalkyl and a group of formula:
hvori in which
R2, R3, R4, R7, Rn og n er som angitt i krav 1, og Z' representerer en gruppe med formel: R2, R3, R4, R7, Rn and n are as stated in claim 1, and Z' represents a group of formula:
R' representerer en tosyl-, mesyl- eller benzensulfonylgruppe og R' represents a tosyl, mesyl or benzenesulfonyl group and
R4 er som angitt over, R4 is as stated above,
reageres med en forbindelse med formel V: is reacted with a compound of formula V:
hvori in which
R2, R3 og R' er som angitt over og R2, R3 and R' are as indicated above and
X representerer en labil gruppe, X represents a labile group,
for oppnåelse av en forbindelse med formel III: for obtaining a compound of formula III:
hvori in which
R2, R3, R4, R'i, Z' og n er som angitt over, R2, R3, R4, R'i, Z' and n are as indicated above,
hvorpå en forbindelse med formel II: wherein a compound of formula II:
hvori R5 er hydrogen og X representerer en labil gruppe eller et aldehyd med formel: wherein R5 is hydrogen and X represents a labile group or an aldehyde of formula:
hvori R5 er som angitt over, reageres i nærvær av hydrogen-cyanid eller cyanidioner med det ovennevnte sykliske amin med formel III for oppnåelse av den ovennevnte forbindelse med formel I. wherein R 5 is as indicated above, is reacted in the presence of hydrogen cyanide or cyanide ions with the above cyclic amine of formula III to obtain the above compound of formula I.
Forbindelsen med formel III hvori Z' har den ovennevnte betydning fremstilles ved å reagere et polyamin med formel IV: The compound of formula III in which Z' has the above meaning is prepared by reacting a polyamine of formula IV:
hvori n, R', R'x og R4 har betydningen som angitt over, wherein n, R', R'x and R4 have the meaning as indicated above,
med en "forbindelse med formel V: with a "compound of formula V:
hvori R2, R3 og R' har betydningen som angitt over og X representerer en labil gruppe som en tosyloksy- eller mesyl-oksygruppe eller et kloratom, bromatom eller jodatom. wherein R 2 , R 3 and R' are as defined above and X represents a labile group such as a tosyloxy or mesyloxy group or a chlorine atom, bromine atom or iodine atom.
Forbindelsen med formel III kan også fremstilles ved å reagere et diamin med formel X: hvori R' 1 og R' har den ovennevnte betydning, med en forbindelse med formel XI: The compound of formula III can also be prepared by reacting a diamine of formula X: in which R' 1 and R' have the above meaning, with a compound of formula XI:
hvori R', R2, R3, R4, X og n er som angitt i det foregående. wherein R', R2, R3, R4, X and n are as indicated above.
Denne cykliseringsreaksjonen gjennomføres fordelaktig i nærvær av en faseoverføringskatalysator. This cyclization reaction is advantageously carried out in the presence of a phase transfer catalyst.
Polyaminene med formel IV kan oppnås fra dihydroksylaminer i overensstemmelse med følgende reaksjonsskjema: The polyamines of formula IV can be obtained from dihydroxylamines in accordance with the following reaction scheme:
Alternativt omsettes ftalimid med forbindelsen med formel VII og hydrazinolyse gjennomføres for å omdanne forbindelsen med formel VII til forbindelsene med formel IX. Alternatively, phthalimide is reacted with the compound of formula VII and hydrazinolysis is carried out to convert the compound of formula VII to the compounds of formula IX.
Forbindelsene med formel III inneholdende to nitrogenholdige ringer kan fremstilles i henhold til fremgangsmåtene som er angitt i det foregående. The compounds of formula III containing two nitrogenous rings can be prepared according to the methods indicated above.
Det er således mulig å reagere et polyamin med formel XII: It is thus possible to react a polyamine of formula XII:
hvori A er C1- Cs alkylen og R' har betydningen som angitt over, med en forbindelse med formel XI for å oppnå forbindelsen med formel III hvori Rn er en gruppe A. wherein A is C1-C8 alkylene and R' is as defined above, with a compound of formula XI to obtain the compound of formula III wherein Rn is a group A.
Polyaminet med formel XII kan fremstilles fra et tetrahalo-genert derivat ved nukleofil substitusjon i nærvær av natriumazid etterfulgt av en reduksjon i nærvær av hydrogen og palladium på karbon. The polyamine of formula XII can be prepared from a tetrahalogenated derivative by nucleophilic substitution in the presence of sodium azide followed by reduction in the presence of hydrogen and palladium on carbon.
Den foreliggende oppfinnelse vedrører også komplekser dannet med ligander med formel I og metallioner valgt blant lanthanidionene med atomnummer 57 til 71, såvel som saltene av disse komplekser med fysiologisk tålbare uorganiske eller organiske baser eller med basiske aminosyrer. The present invention also relates to complexes formed with ligands of formula I and metal ions selected from the lanthanide ions with atomic numbers 57 to 71, as well as the salts of these complexes with physiologically tolerable inorganic or organic bases or with basic amino acids.
I slike komplekser er metallionene særlig gadolinium, europium og dysprosium. In such complexes, the metal ions are particularly gadolinium, europium and dysprosium.
Som eksempler på salter kan man nevne dem som er dannet med natriumhydroksyd, N-metylglukamin, dietanolamin, lysin og arginin. Examples of salts include those formed with sodium hydroxide, N-methylglucamine, diethanolamine, lysine and arginine.
Kompleksene kan fremstilles ved å reagere ligandene med et metallsalt eller metalloksyd i et vandig løsningsmiddel og med eventuell nøytralisering for å danne et salt. The complexes can be prepared by reacting the ligands with a metal salt or metal oxide in an aqueous solvent and with optional neutralization to form a salt.
Oppfinnelsen omfatter ikke bare ligander med formel I og kompleksene som er definert over i form av racemiske blandinger, men også stereoisomerene av disse ligander og komplekser. The invention encompasses not only ligands of formula I and the complexes defined above in the form of racemic mixtures, but also the stereoisomers of these ligands and complexes.
Kompleksene ifølge oppfinnelsen kan være innkapslet og særlig i liposomer. The complexes according to the invention can be encapsulated and especially in liposomes.
Kompleksene ifølge oppfinnelsen som er dannet med ligander med formel I og paramagnetiske ioner, og saltene derav, med fysiologisk tålbare baser kan anvendes som midler for å indusere magnetisk resonans og som reagens for kjemisk skift in vivo. The complexes according to the invention which are formed with ligands of formula I and paramagnetic ions, and the salts thereof, with physiologically tolerable bases can be used as agents for inducing magnetic resonance and as reagents for chemical shift in vivo.
Kompleksene ifølge oppfinnelsen som er dannet med ligander med formel I og med lanthanidioner med atomnummer 57 til 71, og deres salter med fysiologisk tålbare baser, kan anvendes som røntgenkontrastmidler. For dette formål er kompleksene dannet med følgende metallioner særlig foretrukne: Gd, Er, Dy, Tb, Ce og La. The complexes according to the invention which are formed with ligands of formula I and with lanthanide ions with atomic numbers 57 to 71, and their salts with physiologically tolerable bases, can be used as X-ray contrast agents. For this purpose, the complexes formed with the following metal ions are particularly preferred: Gd, Er, Dy, Tb, Ce and La.
Følgelig vedrører den foreliggende oppfinnelse også diagnostiske preparater som kan tilføres til mennesker, omfattende minst ett kompleks dannet med en ligand med formel I og med metallioner valgt fra lanthanidionene med atomnummer 57 til 71, såvel som saltene av disse komplekser med fysiologisk tålbare uorganiske eller organiske baser, eller med basiske aminosyrer. Accordingly, the present invention also relates to diagnostic preparations that can be administered to humans, comprising at least one complex formed with a ligand of formula I and with metal ions selected from the lanthanide ions with atomic numbers 57 to 71, as well as the salts of these complexes with physiologically tolerable inorganic or organic bases , or with basic amino acids.
Disse preparater kan særlig omfatte løsninger av et kompleks i henhold til oppfinnelsen i et fysiologisk tålbart vandig løsningsmiddel. These preparations may in particular comprise solutions of a complex according to the invention in a physiologically tolerable aqueous solvent.
De diagnostiske preparater i henhold til oppfinnelsen kan tilføres: parenteralt omfattende intravenøst, intraarterielt, The diagnostic preparations according to the invention can be administered: parenterally including intravenously, intraarterially,
intralymfatisk, subkutant, intralymphatic, subcutaneous,
oralt, orally,
subaraknoidalt, subarachnoid,
intrabronkialt i form av en aerosol, intrabronchially in the form of an aerosol,
intraartikulært, intra-articular,
lokalt for å synliggjøre hulrom (f.eks. uterus), locally to visualize cavities (e.g. uterus),
for påvisning ved magnetisk resonans, idet dosene varierer avhengig av tilførselsmåten. for detection by magnetic resonance, as the doses vary depending on the method of administration.
For intravenøs og intraarteriell tilførsel er dosene fra 0,01 til 2 mM/kg. For intravenous and intra-arterial administration, the doses are from 0.01 to 2 mM/kg.
For oral tilførsel kan dosene være opptil 10 mM/kg. For oral administration, doses can be up to 10 mM/kg.
For andre tilførselsmåter er dosene som anvendes vanligvis mindre enn 1 mM/kg og ved subaraknoidal tilførsel er dosene vanligvis under 0,05 mM/kg. For other administration methods, the doses used are usually less than 1 mM/kg and for subarachnoid administration the doses are usually below 0.05 mM/kg.
Dosene er de samme ved anvendelse som reagenser for kjemisk skift in vivo og som røntgenkontrastmidler unntatt ved intra-venøs eller intraarteriell tilførsel hvor dosene kan være større enn eller lik 5 mM/kg. The doses are the same when used as reagents for chemical shift in vivo and as X-ray contrast agents except for intra-venous or intra-arterial administration where the doses may be greater than or equal to 5 mM/kg.
De etterfølgende eksempler illustrerer fremstillingen av ligandene i henhold til den foreliggende oppfinnelse. The following examples illustrate the preparation of the ligands according to the present invention.
I disse eksemplene ble: In these examples were:
NMR spektra gjennomført på en Varian EM 3 60 maskin ved 60 Mz med TMs som intern referanse. Dersom ikke NMR spectra carried out on a Varian EM 3 60 machine at 60 Mz with TMs as internal reference. If not
annet er angitt, er løsningsmiddelet CDC13. unless otherwise stated, the solvent is CDC13.
IR spektra ble gjennomført i et Perkins-Elmer 1320 apparat. Spektra for de faste stoffer ble målt i form av KBr skiver. Når det gjelder væsker (oljer) ble de målt i IR spectra were carried out in a Perkins-Elmer 1320 apparatus. Spectra for the solids were measured in the form of KBr disks. As for liquids (oils) they were measured in
fravær av løsningsmiddel. absence of solvent.
Uttrykket "buffer" anvendt i tynnsjiktkromatografi angir The term "buffer" used in thin layer chromatography indicates
en blanding av 1,5 M NH4OH og 1,5 M (NH4)2C03. Smeltepunktene ble målt på en Kofler-blokk. a mixture of 1.5 M NH 4 OH and 1.5 M (NH 4 ) 2 CO 3 . The melting points were measured on a Kofler block.
Uttrykkene som anvendes i forbindelse med analyser under kompleksdannelse: "fravær av fri Gd<3+> og av frie ligander" skal forståes innenfor påvisningsgrensene for de metoder som anvendes, dvs < 4 ppm og < 5 ppm for henholdsvis Gd<3+> og ligand. The expressions used in connection with analyzes during complex formation: "absence of free Gd<3+> and of free ligands" must be understood within the detection limits for the methods used, i.e. < 4 ppm and < 5 ppm for Gd<3+> and respectively ligand.
EKSEMPEL 1 Fremstilling av 2,6-dimetyl-l,4,7,10-tetraaza-cyklododekan-N,N',N'',N'''-tetraeddiksyre. EXAMPLE 1 Preparation of 2,6-dimethyl-1,4,7,10-tetraaza-cyclododecane-N,N',N'',N'''-tetraacetic acid.
a) Fremstilling av N-tosyl-bis (2-tosyloksypropyl)amin. a) Preparation of N-tosyl-bis(2-tosyloxypropyl)amine.
En løsning av 53,2 g (0,4 mol) diisopropanolamin i 50 cm<3>A solution of 53.2 g (0.4 mol) of diisopropanolamine in 50 cm<3>
pyridin tilsettes dråpevis under avkjøling til en løsning av 248 g (1,3 mol) tosylklorid i 200 cm<3> pyridin ved 0°C slik at temperaturen holdes mellom 1 og 5°C. Blandingen får stå ved denne temperatur i 72 timer. Den helles deretter inn i 2 1 isvann og 250 cm<3> konsentrert saltsyre. pyridine is added dropwise while cooling to a solution of 248 g (1.3 mol) tosyl chloride in 200 cm<3> pyridine at 0°C so that the temperature is kept between 1 and 5°C. The mixture is allowed to stand at this temperature for 72 hours. It is then poured into 2 l of ice water and 250 cm<3> of concentrated hydrochloric acid.
Det tosylerte derivat ekstraheres med 2 1 metylenklorid. Den organiske fase tørkes over natriumsulfat, filtreres og avfarges med 3 SA trekull og refiltreres gjennom et lag av silika. Etter avdamping av saltet ble det tilbake 193,8 g av en gul olje (utbytte 81 %, Rf=0,7, silika/CH2Cl2/aceton/98/2) som anvendes i neste trinn uten ytterligere rensing. The tosylated derivative is extracted with 2 1 methylene chloride. The organic phase is dried over sodium sulfate, filtered and decolorized with 3 SA charcoal and refiltered through a layer of silica. After evaporation of the salt, 193.8 g of a yellow oil remained (yield 81%, Rf=0.7, silica/CH2Cl2/acetone/98/2) which is used in the next step without further purification.
<1>HMNR spektrum: 6H CH3 (dublett 1,1 og 1,3 ppm), 9H CH3 tosyl (singlett 2,5 ppm), 4H CH2 (multiplett med senter i 3,3 ppm), 2H CH (kvadruplett mellom 4,7 og 5,1 ppm), 12H aromatiske forbindelser (multiplett 7,3 og 8 ppm). <1>HMNR spectrum: 6H CH3 (doublet 1.1 and 1.3 ppm), 9H CH3 tosyl (singlet 2.5 ppm), 4H CH2 (multiplet centered at 3.3 ppm), 2H CH (quadruplet between 4 .7 and 5.1 ppm), 12H aromatic compounds (multiplet 7.3 and 8 ppm).
b) Fremstilling av N-tosyl-bis(2-azidopropyl)amin. b) Preparation of N-tosyl-bis(2-azidopropyl)amine.
Til 193,8 g (0,32 mol) av forbindelsen oppnådd ia) i 1,2 1 To 193.8 g (0.32 mol) of the compound obtained in ia) in 1.2 1
acetonitril og 300 cm<3> vann tilsettes 65,1 g natriumazid acetonitrile and 300 cm<3> of water are added to 65.1 g of sodium azide
(1 mol). Blandingen omrøres og oppvarmes ved 75°C i 48 timer. Etter avkjøling avdampes acetonitril i vakuum. (1 mole). The mixture is stirred and heated at 75°C for 48 hours. After cooling, the acetonitrile is evaporated in vacuo.
Resten tas opp ill metylenklorid. Den organiske fase vaskes med vann, tørkes og filtreres gjennom et silikalag (200 g). Etter avdamping oppnås 82 g av en klar gul olje (utbytte 75 %, Rf=0,85, silika/CH2Cl2/aceton/92/2) som er tilstrekkelig ren til å bli anvendt direkte. The remainder is taken up in methylene chloride. The organic phase is washed with water, dried and filtered through a layer of silica (200 g). After evaporation, 82 g of a clear yellow oil are obtained (yield 75%, Rf=0.85, silica/CH2Cl2/acetone/92/2) which is sufficiently pure to be used directly.
IR spektrum N3=2100 cm"<1>, kraftig. IR spectrum N3=2100 cm"<1>, powerful.
c) Fremstilling av N-tosyl-bis(2-aminopropyl)amin. c) Preparation of N-tosyl-bis(2-aminopropyl)amine.
82,2 g (0,244 mol) av forbindelsen oppnådd i b) oppløses i 82.2 g (0.244 mol) of the compound obtained in b) are dissolved in
500 cm<3> etanol inneholdende 8 g 5 % palladium på karbon ved 50 % fuktighet. 500 cm<3> of ethanol containing 8 g of 5% palladium on carbon at 50% humidity.
Blandingen omrøres kraftig mens en forsiktig hydrogenstrøm føres gjennom (fjerning av nitrogen som frigjøres). Etter åtte timer ved omgivelsestemperatur, viser TLC fravær av azid-funksjonen. Blandingen filtreres deretter og avdampes. Det oppnås 68,4 g av en klar gul olje (utbytte 98,5 %; Rf=0,6, silika/MeOH/NH4OH/95/5) som anvendes videre uten rensing. The mixture is stirred vigorously while a gentle stream of hydrogen is passed through (removal of liberated nitrogen). After eight hours at ambient temperature, TLC shows the absence of the azide function. The mixture is then filtered and evaporated. 68.4 g of a clear yellow oil is obtained (yield 98.5%; Rf=0.6, silica/MeOH/NH4OH/95/5) which is used further without purification.
NMR spektrum: 6H CH3 (dublett 0,9 og 1 ppm); 3H CH3 tosyl (singlett 2,4 ppm), 6H CH2 og CH (kompleks multiplett mellom 2,7 og 3,2 ppm), 4H aromatiske forbindelser (multiplett mellom 7,1 og 7,7 ppm). NMR spectrum: 6H CH3 (doublet 0.9 and 1 ppm); 3H CH3 tosyl (singlet 2.4 ppm), 6H CH2 and CH (complex multiplet between 2.7 and 3.2 ppm), 4H aromatic compounds (multiplet between 7.1 and 7.7 ppm).
d) Fremstilling av N-tosyl-bis[(tosylamino)propyl]amin. d) Preparation of N-tosyl-bis[(tosylamino)propyl]amine.
93 g (0,5 mol) tosylklorid tilsettes i porsjoner til 68,4 g 93 g (0.5 mol) of tosyl chloride are added in portions to 68.4 g
(0,24 mol) av aminet oppnådd i c), i 500 cm<3> metylenklorid og (0.24 mol) of the amine obtained in c), in 500 cm<3> methylene chloride and
70 cm<3> (0,5 mol) trietylamin ved 0°C. Etter endt tilsetning omrøres blandingen i seks timer ved omgivelsestemperatur. Reaksjonsblandingen vaskes deretter med 600 cm<3> vann, den organiske fase tørkes, avdampes til tørrhet og resten kromatograferes på en silikagelkolonne med ren metylenklorid, deretter med en metylenklorid/metanol/92/2 blanding. Fraksjonene av interesse avdampes og den faste rest rekrystalliseres fra etanol. Etter filtrering og tørking er den oppnådde masse 99,1 g (utbytte 70 %). 70 cm<3> (0.5 mol) of triethylamine at 0°C. After the addition is complete, the mixture is stirred for six hours at ambient temperature. The reaction mixture is then washed with 600 cm<3> of water, the organic phase is dried, evaporated to dryness and the residue is chromatographed on a silica gel column with pure methylene chloride, then with a methylene chloride/methanol/92/2 mixture. The fractions of interest are evaporated and the solid residue recrystallized from ethanol. After filtration and drying, the obtained mass is 99.1 g (yield 70%).
NMR spektrum: 6H CH3 (dublett 0,9, 1 ppm), 9H CH3 p-tosyl (singlett 2,4 ppm), 4H CH2 (triplett med senter i 2,9 ppm), NMR spectrum: 6H CH3 (doublet 0.9, 1 ppm), 9H CH3 p-tosyl (singlet 2.4 ppm), 4H CH2 (triplet centered at 2.9 ppm),
2H CH (dublett 3,3 og 3,5 ppm), 12H aromatiske forbindelser (multiplett med senter i 7,4 ppm). 2H CH (doublet 3.3 and 3.5 ppm), 12H aromatics (multiplet centered at 7.4 ppm).
e) Fremstilling av N-tosyl-bis(2-tosyloksyetyl)amin. e) Preparation of N-tosyl-bis(2-tosyloxyethyl)amine.
En løsning av 32,5 g (0,31 mol) dietanolamin i 60 cm<3> pyridin A solution of 32.5 g (0.31 mol) diethanolamine in 60 cm<3> pyridine
tilsettes sakte til en løsning av 185 g (0,97 mol) tosylklorid i 22 0 cm<3> pyridin ved 0°C slik at temperaturen ikke over-skrider 5°C. Etter endt tilsetning holdes blandingen ved denne temperatur i en time, deretter helles den over i 220 cm<3 >isavkjølt vann under kraftig omrøring. Etter filtrering, vasking og tørking oppnås 148,4 g presipitat (utbytte 85 %, Rf=0,6, silika/CH2Cl2/aceton/98/2). is added slowly to a solution of 185 g (0.97 mol) tosyl chloride in 220 cm<3> pyridine at 0°C so that the temperature does not exceed 5°C. After the addition is complete, the mixture is kept at this temperature for one hour, then it is poured into 220 cm3 of ice-cooled water with vigorous stirring. After filtration, washing and drying, 148.4 g of precipitate are obtained (yield 85%, Rf=0.6, silica/CH2Cl2/acetone/98/2).
NMR spektrum: 9H CH3 tosyl (singlett 2,4 ppm), 4H CH2N (triplett ved 3,4 ppm), 4H CH2 (triplett ved 4,1 ppm), 12H aromatiske forbindelser (multiplett mellom 7,1 og 7,7 ppm). f) Fremstilling av N,N',N'',N' "-tetratosyl-2,6-dimetyl-1,4,7,10-tetraazacyklododekan. NMR spectrum: 9H CH3 tosyl (singlet 2.4 ppm), 4H CH2N (triplet at 3.4 ppm), 4H CH2 (triplet at 4.1 ppm), 12H aromatic compounds (multiplet between 7.1 and 7.7 ppm ). f) Preparation of N,N',N'',N'"-tetratosyl-2,6-dimethyl-1,4,7,10-tetraazacyclododecane.
65 g (0,11 mol) av forbindelsen oppnådd i d) oppløst i 500 cm<3 >tørr DMF tilsettes dråpevis til 8,8. g (0,22 mol) av en 60 % suspensjon av NaH i olje i 50 cm<3> DMF. Tilsetningen gjennom-føres ved omgivelsestemperatur og på en slik måte at man har en stabil frigjøring av hydrogen. Etter endt tilsetning oppvarmes blandingen til 100°C og en løsning av 68,1 g 65 g (0.11 mol) of the compound obtained in d) dissolved in 500 cm<3> of dry DMF is added dropwise to 8.8. g (0.22 mol) of a 60% suspension of NaH in oil in 50 cm<3> DMF. The addition is carried out at ambient temperature and in such a way that there is a stable release of hydrogen. After the addition is complete, the mixture is heated to 100°C and a solution of 68.1 g
(0,12 mol) av forbindelsen oppnådd i e) oppløst i 500 cm<3> tørr DMF tilsettes dråpevis. Reaksjonsblandingen holdes deretter ved denne temperatur i 24 timer med kraftig omrøring. (0.12 mol) of the compound obtained in e) dissolved in 500 cm<3> of dry DMF is added dropwise. The reaction mixture is then kept at this temperature for 24 hours with vigorous stirring.
Løsningsmiddelet avdampes deretter i vakuum og resten tas opp i en CH2C12/H20 blanding. Den organiske fase vaskes med vann, tørkes og avdampes til tørrhet. Resten (100 g) rekrystalliseres fra isopropanol, deretter fra toluen til å gi, etter filtrering, vasking med isopropyleter og tørking, 36 g av et hvitt faststoff (utbytte 40 %, Rf=0,5-0,6, silika/CH2Cl2/- aceton/98/2). The solvent is then evaporated in vacuo and the residue taken up in a CH2C12/H20 mixture. The organic phase is washed with water, dried and evaporated to dryness. The residue (100 g) is recrystallized from isopropanol, then from toluene to give, after filtration, washing with isopropyl ether and drying, 36 g of a white solid (yield 40%, Rf=0.5-0.6, silica/CH2Cl2/ - acetone/98/2).
NMR spektrum: 6H CH3 (dublett ved 1 og 1,2 ppm), 12H CH3 tosyl (singlett 2,4 ppm), 14H CH2 og CH (multiplett mellom 3 og 4,5 ppm), 16H aromatiske forbindelser (multiplett mellom 7,1 og 7,7 ppm). g) Fremstilling av N,N',N'',N'''-tetratosyl-2,6-dimetyl-1,4,7,10-tetraazacyklododekan (variant). NMR spectrum: 6H CH3 (doublet at 1 and 1.2 ppm), 12H CH3 tosyl (singlet 2.4 ppm), 14H CH2 and CH (multiplet between 3 and 4.5 ppm), 16H aromatic compounds (multiplet between 7, 1 and 7.7 ppm). g) Preparation of N,N',N'',N'''-tetratosyl-2,6-dimethyl-1,4,7,10-tetraazacyclododecane (variant).
En nylaget løsning av natriumetylat (60 mmol) i 200 cm<3> tørr DMF tilsettes hurtig til en løsning av 17 g (28,7 mmol) av forbindelsen oppnådd i d) i 100 cm<3> etanol ved tilbakeløp. Den oppnådde blanding blir klar og behandles med tilbakeløp i en til to timer. Løsningsmidlene avdampes til tørrhet, resten oppløses i 200 cm<3> DMF og oppvarmes til 100°C. En løsning av 17 g (30 mmol) av forbindelsen oppnådd i e) i 100 cm<3> DMF tilsettes til denne løsning i løpet av en halv time. Reaksjonsblandingen holdes ved 100°C over natten. DMF avdampes deretter og resten tas opp i en H20/CH2C12 blanding. Produktet fra den organiske fase kromatograferes på en silikagelkolonne med blandingen CH2Cl2/etylacetat/98/2 som elueringsmiddel. Produktet rekrystalliseres fra isopropyleter og veier 13,5 g etter tørking (utbytte 58 %, Rf=0,5-0,6, silika/CH2Cl2/- aceton/98/2). A freshly prepared solution of sodium ethylate (60 mmol) in 200 cm<3> dry DMF is quickly added to a solution of 17 g (28.7 mmol) of the compound obtained in d) in 100 cm<3> ethanol at reflux. The resulting mixture becomes clear and is refluxed for one to two hours. The solvents are evaporated to dryness, the residue is dissolved in 200 cm<3> DMF and heated to 100°C. A solution of 17 g (30 mmol) of the compound obtained in e) in 100 cm<3> DMF is added to this solution over the course of half an hour. The reaction mixture is kept at 100°C overnight. The DMF is then evaporated and the residue taken up in a H20/CH2C12 mixture. The product from the organic phase is chromatographed on a silica gel column with the mixture CH2Cl2/ethyl acetate/98/2 as eluent. The product is recrystallized from isopropyl ether and weighs 13.5 g after drying (yield 58%, Rf=0.5-0.6, silica/CH2Cl2/-acetone/98/2).
Spekter som er identisk med det oppnådd i f). Spectrum identical to that obtained in f).
h) Fremstilling av 2,6-dimetyl-l,4,7,10-tetraazacyklo-dodekan. 33 g av forbindelsen oppnådd i f) eller g) oppløses i 80 cm<3 >98 % svovelsyre og oppvarmes ved 100°C i en argonatmosfære i 72 timer. Etter avkjøling, tilsettes reaksjonsblandingen dråpevis til 1 1 etyleter ved 0°C. Det oppnådde 2,6-dimetyl-1,4,7,10-tetraazacyklododekansulfat filtreres fra, tas opp i vann, nøytraliseres med natriumhydroksyd og ekstraheres med CH2C12. De organiske faser kombineres og avdampes til tørr-het, og oppnådd faststoff i en mengde på 6 g anvendes h) Preparation of 2,6-dimethyl-1,4,7,10-tetraazacyclododecane. 33 g of the compound obtained in f) or g) are dissolved in 80 cm<3>98% sulfuric acid and heated at 100°C in an argon atmosphere for 72 hours. After cooling, the reaction mixture is added dropwise to 1 1 of ethyl ether at 0°C. The 2,6-dimethyl-1,4,7,10-tetraazacyclododecane sulfate obtained is filtered off, taken up in water, neutralized with sodium hydroxide and extracted with CH 2 Cl 2 . The organic phases are combined and evaporated to dryness, and the obtained solid in an amount of 6 g is used
uten ytterligere rensing (utbytte 75 %, Rf=0,65, aluminium-oksyd/bu tano 1/vann/eddiksyre/50/25/11). without further purification (yield 75%, Rf=0.65, aluminum oxide/butane 1/water/acetic acid/50/25/11).
NMR spektrum ( (D20) : 6H CH3 (dublett 0,9 til 1 ppm), 14H CH2 og CH (multiplett med senter i 2,5 ppm). NMR spectrum ( (D2O) : 6H CH3 (doublet 0.9 to 1 ppm), 14H CH2 and CH (multiplet centered at 2.5 ppm).
i) Fremstilling av 2,6-dimetyl-l,4,7,10-tetraazacyklo-dodekan-N,N',N'',N'''-tetraeddiksyre. i) Preparation of 2,6-dimethyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid.
En blanding av 5,7 g (60 mmol) monokloreddiksyre og 3,4 g A mixture of 5.7 g (60 mmol) monochloroacetic acid and 3.4 g
(60 mmol) kaliumhydroksyd i 25 cm<3> vann tilsettes til en løsning av 3 g (15 mmol) av forbindelsen oppnådd i h) i 25 cm<3 >vann. Den oppnådde blanding oppvarmes til 60°C og en løsning av natriumhydroksyd (3,4 g, 60 mol) i 25 cm<3> vann tilsettes slik av pH holdes mellom 9 og 10. Tilsetningen krever åtte timer. Etter at tilsetningen av kaliumhydroksyd er fullstendig, opprettholdes oppvarmingen i 24 timer. Etter avkjøling, bringes pH til 2,5 med konsentrert HCl. Det dannede presipitat filtreres fra, vaskes med iskaldt vann og veier 3 g etter tørking (utbytte:35 %, Rf=0,33, silika/etylacetat/isopropanol/ammoniakk/12/35/30). Denne forbindelsen tilsvarer komplekset av 2,6-dimetyl-l,4,7,10-tetraazacyklododekan-N,N',N'',N'''-tetraeddiksyre med 2 KC1. (60 mmol) of potassium hydroxide in 25 cm<3> of water is added to a solution of 3 g (15 mmol) of the compound obtained in h) in 25 cm<3> of water. The resulting mixture is heated to 60°C and a solution of sodium hydroxide (3.4 g, 60 mol) in 25 cm<3> of water is added so that the pH is kept between 9 and 10. The addition requires eight hours. After the addition of potassium hydroxide is complete, heating is maintained for 24 hours. After cooling, bring the pH to 2.5 with concentrated HCl. The precipitate formed is filtered off, washed with ice-cold water and weighs 3 g after drying (yield: 35%, Rf=0.33, silica/ethyl acetate/isopropanol/ammonia/12/35/30). This compound corresponds to the complex of 2,6-dimethyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid with 2 KCl.
9,5 g av dette kompleks elueres med 200 cm<3> 10% eddiksyre fra en ionebytterharpiks IRA 958 (OH) som var regenerert på forhånd med IN NaOH og vasket med vann inntil nøytralitet. 9.5 g of this complex is eluted with 200 cm<3> of 10% acetic acid from an ion exchange resin IRA 958 (OH) which was regenerated beforehand with 1N NaOH and washed with water until neutrality.
De oppnådde fraksjoner avdampes til tørrhet og opptas tre ganger i 50 cm<3> vann for å eliminere spor av eddiksyre. Den oppnådde rest gnis ut med etyleter (100 cm<3>) til å gi, etter filtrering og tørking, 6,3 g av et hvitt faststoff. The fractions obtained are evaporated to dryness and taken up three times in 50 cm<3> of water to eliminate traces of acetic acid. The residue obtained is triturated with ethyl ether (100 cm<3>) to give, after filtration and drying, 6.3 g of a white solid.
Utbytte: 89 %. Yield: 89%.
NMR spektrum: (D20) 6H CH3 (dublett 1,4 og 1,5 ppm); 14H CH2 og CH (kompleks multiplett med senter i 3,6 ppm), 8H CH2C00H (dublett ved 3,8 ppm). NMR spectrum: (D 2 O) 6 H CH 3 (doublet 1.4 and 1.5 ppm); 14H CH2 and CH (complex multiplet centered at 3.6 ppm), 8H CH2C00H (doublet at 3.8 ppm).
EKSEMPEL 2 Fremstilling av gadoliniumkomplekset av 2,6-dimetyl-1,4,7,10-tetraazacyklododekan-N,N',N'', EXAMPLE 2 Preparation of the gadolinium complex of 2,6-dimethyl-1,4,7,10-tetraazacyclododecane-N,N',N'',
N'''-tetraeddiksyre (metylglukaminsalt). N'''-tetraacetic acid (methylglucamine salt).
En suspensjon av 5,425 g (12,54 mmol) 2,6-dimetyl-l,4,7,10-tetraazacyklododekan-N, N',N'',N'''-tetraeddiksyre oppnådd i eksempel li) og 2,27 g Gd203 (6,27 mmol) i 125 cm<3> vann, oppvarmes ved 65°C i 24 timer. pH innstilles deretter til 7,4 ved tilsetning av metylglukamin. Etter bestemmelse av fri Gd<3+> ved xy1enolorange/EDTA metoden, tilsettes 650 g 2,6-dimetyl-1,4,7,10-tetraazacyklododekan-N,N',N'',N'''-tetra-eddiksyre (1,5 mmol) for å kompleksdanne det gjenværende gadolinium. Fullføring av kompleksdanneIse bekreftes ved fravær av fri Gd<3+> (bestemmes ved xylenolorange) og av frie ligander (kompleksometrisk bestemmelse med Cu<2+>). Bestemmelsen av totalt gadolinium i løsningen gjennomføres ved atomemisjonsspektroskopi i DCP på et Epectrospan 4 Beckmann-apparat. Kvantitativt utbytte: Rf=0,49, silika/etylacetat/- isopropanol/ammoniakk/12/35/30. A suspension of 5.425 g (12.54 mmol) of 2,6-dimethyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid obtained in example li) and 2, 27 g of Gd2O3 (6.27 mmol) in 125 cm<3> of water, heated at 65°C for 24 hours. The pH is then adjusted to 7.4 by adding methylglucamine. After determination of free Gd<3+> by the xy1enolorange/EDTA method, 650 g of 2,6-dimethyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetra- acetic acid (1.5 mmol) to complex the remaining gadolinium. Completion of complex formation is confirmed by the absence of free Gd<3+> (determined by xylenol orange) and of free ligands (complexometric determination with Cu<2+>). The determination of total gadolinium in the solution is carried out by atomic emission spectroscopy in DCP on an Epectrospan 4 Beckmann apparatus. Quantitative yield: Rf=0.49, silica/ethyl acetate/isopropanol/ammonia/12/35/30.
EKSEMPEL 3 Fremstilling av 2-heksyl-l,4,7,10-tetraaza-cyklododekan-N, N',N'',N' "-tetraeddiksyre. a) Fremstilling av N-(2-hydroksyetyl)-N-(2-heksyl-2-hydroksyetyl)amin. 50 g (0,39 mmol) 1,2-epoksyoktan tilsettes dråpevis til 250 cm<3> (4 mol) etanolamin ved 100°C. Oppvarmingen opprettholdes i en time etter endt tilsetning og overskudd etanolamin destilleres i vakuum. Resten rekrystalliseres fra 600 cm<3 >heksan, etter filtrering og tørking. Den faste rest hadde en vekt på 69 g (smeltepunkt 45°C, utbytte: 93 %, Rf=0,62, silika/butanol/H20/eddiksyre/50/25/11. EXAMPLE 3 Preparation of 2-hexyl-1,4,7,10-tetraaza-cyclododecane-N,N',N'',N'"-tetraacetic acid. a) Preparation of N-(2-hydroxyethyl)-N-( 2-hexyl-2-hydroxyethyl)amine. 50 g (0.39 mmol) of 1,2-epoxyoctane is added dropwise to 250 cm<3> (4 mol) of ethanolamine at 100° C. The heating is maintained for one hour after the addition is complete and excess ethanolamine is distilled in vacuo. The residue is recrystallized from 600 cm<3 >hexane, after filtration and drying. The solid residue had a weight of 69 g (melting point 45°C, yield: 93%, Rf=0.62, silica/butanol /H20/acetic acid/50/25/11.
NMR spektrum: 3H CH3 (triplett 0,9 ppm), 10H CH2 kjede (stor singlett ved 2,2 ppm), 7H CH2 og CH (to dårlig oppløste masser . ved 2,8 og 3,8 ppm). b) Fremstilling av N-tosyl-N-(2-tosyloksyetyl)-N-(2-heksyl-2-tosyloksyetylamin. NMR spectrum: 3H CH3 (triplet 0.9 ppm), 10H CH2 chain (large singlet at 2.2 ppm), 7H CH2 and CH (two poorly resolved masses at 2.8 and 3.8 ppm). b) Preparation of N-tosyl-N-(2-tosyloxyethyl)-N-(2-hexyl-2-tosyloxyethylamine).
47,3 g (0,25 mol) av forbindelsen oppnådd i a) tilsettes i små mengder til en løsning av 156 g (0,82 mol) tosylklorid i 300 cm<3> pyridin ved 0°C i løpet av en time. Blandingen holdes ved 0°C i to døgn, deretter helles den over i en blanding av is og HC1 (2/1) . Produktet ekstraheres med CH2C12, og kromatograferes deretter på en silikagelkolonne med CH2C12 som elueringsmiddel. Oppnådd masse er 118 g (utbytte: 72%, Rf=0,6, silika/CH2Cl2/aceton/98/2). 47.3 g (0.25 mol) of the compound obtained in a) are added in small amounts to a solution of 156 g (0.82 mol) tosyl chloride in 300 cm<3> pyridine at 0°C over the course of one hour. The mixture is kept at 0°C for two days, then it is poured into a mixture of ice and HC1 (2/1). The product is extracted with CH2C12, and then chromatographed on a silica gel column with CH2C12 as eluent. Mass obtained is 118 g (yield: 72%, Rf=0.6, silica/CH2Cl2/acetone/98/2).
NMR spektrum: 3H CH3 kjede (triplett ved 0,9 ppm), 10H CH2 kjede (stor singlett ved 1,3 ppm), 9H CH3 tosyl (singlett ved 2,4 ppm), 4H CH2N (dårlig oppløst triplett ved 3,4 ppm), 3H CH20 og CH (multiplett ved 4,2 ppm), 12 H aromatiske forbindelser (multiplett mellom 7 og 7,7 ppm). c) Fremstilling av N-tosyl-N- (2-azidoetyl) -N- (2-heksyl-2-azidoetyl)amin. NMR spectrum: 3H CH3 chain (triplet at 0.9 ppm), 10H CH2 chain (large singlet at 1.3 ppm), 9H CH3 tosyl (singlet at 2.4 ppm), 4H CH2N (poorly resolved triplet at 3.4 ppm), 3H CH2O and CH (multiplet at 4.2 ppm), 12 H aromatic compounds (multiplet between 7 and 7.7 ppm). c) Preparation of N-tosyl-N-(2-azidoethyl)-N-(2-hexyl-2-azidoethyl)amine.
87 g (0,133 mol) av forbindelsen oppnådd i b) og 29,25 g 87 g (0.133 mol) of the compound obtained in b) and 29.25 g
(0,5 mol) natriumazid blandes med 350 cm<3> acetonitril og (0.5 mol) of sodium azide is mixed with 350 cm<3> of acetonitrile and
80 cm<3> vann. Blandingen oppvarmes ved 65°C i tre døgn. Acetonitril avdampes deretter i vakuum og resten tas opp i CH2C12. Den organiske fase vaskes med vann, tørkes og avdampes. Det oppnås 50 % av en gul olje som anvendes uten rensing (utbytte: 95 %, Rf=0,75, silika/CH2Cl2/aceton/98/2). 80 cm<3> of water. The mixture is heated at 65°C for three days. Acetonitrile is then evaporated in vacuo and the residue is taken up in CH2C12. The organic phase is washed with water, dried and evaporated. 50% of a yellow oil is obtained which is used without purification (yield: 95%, Rf=0.75, silica/CH2Cl2/acetone/98/2).
NMR spektrum: 3H CH3 kjede (triplett ved 0,9 ppm), 10H CH2 kjede (multiplett ved 1,4 ppm), 3H CH3 tosyl (singlett ved 2,4 ppm), 5H CH2 og CH (kompleks multiplett ved 3,4 ppm), 4H aromatiske forbindelser (multiplett mellom 7,1 og 7,7 ppm). NMR spectrum: 3H CH3 chain (triplet at 0.9 ppm), 10H CH2 chain (multiplet at 1.4 ppm), 3H CH3 tosyl (singlet at 2.4 ppm), 5H CH2 and CH (complex multiplet at 3.4 ppm), 4H aromatic compounds (multiplet between 7.1 and 7.7 ppm).
IR spektrum N3 = 2100 cm"<1>, sterk. IR spectrum N3 = 2100 cm"<1>, strong.
d) Fremstilling av N-tosyl-N-(2-aminoetyl)-N-(2-heksyl-2-aminietyl) amin. 71 g (0,18 mol) av diazidet oppnådd i c) oppløses i 500 cm<3 >etanol hvortil 5 g palladium på karbon med 50 % fuktighet er blitt tilsatt. Suspensjonen omrøres meget kraftig under en strøm av hydrogen ved omgivelsetemperatur i 24 timer. Kataly-satoren fjernes ved filtrering. Etter avdamping av etanol oppnås 61,5 g diamin som anvendes uten rensing (utbytte: kvantitativt, Rf=0,51, silika/MeOH/NH4OH/95/5) . e) Fremstilling av N-tosyl-N-(tosylaminoetyl)-N-(2-heksyl-2-tosylaminoetyl) amin. d) Preparation of N-tosyl-N-(2-aminoethyl)-N-(2-hexyl-2-aminoethyl)amine. 71 g (0.18 mol) of the diazide obtained in c) is dissolved in 500 cm<3 >ethanol to which 5 g palladium on carbon with 50% moisture has been added. The suspension is stirred very vigorously under a stream of hydrogen at ambient temperature for 24 hours. The catalyst is removed by filtration. After evaporating the ethanol, 61.5 g of diamine is obtained which is used without purification (yield: quantitative, Rf=0.51, silica/MeOH/NH4OH/95/5). e) Preparation of N-tosyl-N-(tosylaminoethyl)-N-(2-hexyl-2-tosylaminoethyl)amine.
68,6 g (0,36 mol) tosylklorid tilsettes i porsjoner til en løsning av 61,5 g (0,18 mol) av forbindelsen oppnådd i d) i 500 cm<3> CH2C12 og 52,5 cm<3> (0,38 mol) trietylamin ved 0°C. Etter omrøring i to timer ved omgivelsetemperatur, behandles reaksjonsblandingen med 500 cm<3> vann. Den organiske fase vaskes med vann, tørkes og avdampes. Den oljeaktige rest kromatograferes på en silikagelkolonne med CH2C12 som elueringsmiddel. Oljen som er oppnådd etter avdamping av løs-ningsmiddelet og som er tatt opp i isopropyleter gir 60 g av et hvitt faststoff (smeltepunkt 120°C, utbytte: 51 %, Rf=0,6, silika/CH2Cl2/MeOH/98/2) . 68.6 g (0.36 mol) of tosyl chloride is added in portions to a solution of 61.5 g (0.18 mol) of the compound obtained in d) in 500 cm<3> CH2C12 and 52.5 cm<3> (0 .38 mol) of triethylamine at 0°C. After stirring for two hours at ambient temperature, the reaction mixture is treated with 500 cm<3> of water. The organic phase is washed with water, dried and evaporated. The oily residue is chromatographed on a silica gel column with CH 2 Cl 2 as eluent. The oil obtained after evaporation of the solvent and taken up in isopropyl ether gives 60 g of a white solid (melting point 120°C, yield: 51%, Rf=0.6, silica/CH2Cl2/MeOH/98/2 ).
NMR spektrum: 13H heksylkjede (dårlig oppløst multiplett med senter i 1 ppm), 9H CH3 tosyl (singlett ved 2,4 ppm), 7H CH2 og CH (multiplett med senter i 3,1 ppm). f) Fremstilling av N,N',N" ,N'"-tetratosyl-2-heksyl-1,4,7,10-tetraazacyklododekan. NMR spectrum: 13H hexyl chain (poorly resolved multiplet centered at 1 ppm), 9H CH3 tosyl (singlet at 2.4 ppm), 7H CH2 and CH (multiplet centered at 3.1 ppm). f) Preparation of N,N',N",N'"-tetratosyl-2-hexyl-1,4,7,10-tetraazacyclododecane.
En blanding av 46,5 g (71,5 mmol) av forbindelsen oppnådd i A mixture of 46.5 g (71.5 mmol) of the compound obtained in
d) i det foregående, 41,5 g (73 mmol) av forbindelsen oppnådd i eksempel le) og 24 g (70 mmol) tetrabutylammoniumhydrogen-sulfat oppløses i 400 cm<3> toluen og 200 cm<3> 20 % natriumhydroksyd. Blandingen omrøres kraftig ved 70°C i 24 timer. Etter avkjøling, vaskes den organiske fase med vann, tørkes og avdampes. Resten krystalliseres i etanol, og kromatograferes deretter på en silikagelkolonne med CH2C12 som emuleringsmid-del. 35 g faststoff oppnås (smeltepunkt 154/161°C) . d) in the preceding, 41.5 g (73 mmol) of the compound obtained in example le) and 24 g (70 mmol) of tetrabutylammonium hydrogen sulfate are dissolved in 400 cm<3> toluene and 200 cm<3> 20% sodium hydroxide. The mixture is stirred vigorously at 70°C for 24 hours. After cooling, the organic phase is washed with water, dried and evaporated. The residue is crystallized in ethanol, and then chromatographed on a silica gel column with CH 2 Cl 2 as emulsifier. 35 g of solid is obtained (melting point 154/161°C).
Utbytte: 56 %, Rf=0,55, silika/CH2Cl2/aceton/98/2. Yield: 56%, Rf=0.55, silica/CH2Cl2/acetone/98/2.
NMR spektrum: 3H CH3 kjede (triplett ved 0,9 ppm), 10H CH2 kjede (multiplett ved 1,3 ppm), 12H CH3 tosyl (singlett ved 2,4 ppm), 15H CH2 og CH ring (multiplett ved 3,3 ppm), 16H aromatiske forbindelser (multiplett mellom 7,1 og 7,7 ppm). g) Fremstilling av 2-heksyl-l,4,7,10-tetraazacyklododekan. NMR spectrum: 3H CH3 chain (triplet at 0.9 ppm), 10H CH2 chain (multiplet at 1.3 ppm), 12H CH3 tosyl (singlet at 2.4 ppm), 15H CH2 and CH ring (multiplet at 3.3 ppm), 16H aromatic compounds (multiplet between 7.1 and 7.7 ppm). g) Preparation of 2-hexyl-1,4,7,10-tetraazacyclododecane.
12 g (13 mmol) av forbindelsen oppnådd i f) oppvarmes ved 12 g (13 mmol) of the compound obtained in f) is heated by
100°C i 40 cm<3> 98 % svovelsyre under argon i 24 timer. Etter avkjøling tilsettes blandingen dråpesvis til 500 ml etyleter ved 0°C. Det oppnådde sulfat filtreres, nøytraliseres deretter ved hjelp av en 10 % løsning av natriumhydroksyd og ekstraheres med CH2C12. Den organiske fase tørkes over natriumsulfat, avdampes til tørrhet til å gi 2 g av et krem-farget faststoff (utbytte: 57 %, Rf=0,75, aluminiumoksyd/- butanol/vann/eddiksyre/50/25/11) . 100°C in 40 cm<3> 98% sulfuric acid under argon for 24 hours. After cooling, the mixture is added dropwise to 500 ml of ethyl ether at 0°C. The sulfate obtained is filtered, then neutralized with a 10% solution of sodium hydroxide and extracted with CH 2 Cl 2 . The organic phase is dried over sodium sulfate, evaporated to dryness to give 2 g of a cream-colored solid (yield: 57%, Rf=0.75, alumina/-butanol/water/acetic acid/50/25/11).
Forbindelsen lagres i form av oksalatet ved å omsette en etanolløsning av oksalsyre med 2-heksyl-l,4,7,10-tetraaza-cyklododekan over natten ved omgivelsestemperatur. Oksalatet presipiterer i form av et hvitt faststoff. h) Fremstilling av 2-heksyl-l,4,7,10-tetraazacyklododekan-N,N',N<#>',N<#>''-tetraeddiksyre. The compound is stored in the form of the oxalate by reacting an ethanol solution of oxalic acid with 2-hexyl-1,4,7,10-tetraaza-cyclododecane overnight at ambient temperature. The oxalate precipitates as a white solid. h) Preparation of 2-hexyl-1,4,7,10-tetraazacyclododecane-N,N',N<#>',N<#>''-tetraacetic acid.
En løsning av 1,09 g (2,8 mmol) av oksalatet. oppnådd i g) i 13 cm<3> vann og 20 ml etanol nøytraliseres med 470 mg A solution of 1.09 g (2.8 mmol) of the oxalate. obtained in g) in 13 cm<3> of water and 20 ml of ethanol is neutralized with 470 mg
(8,4 mmol) kaliumhydroksyd. Til denne løsning tilsettes kaliummonokloracetat fremstilt fra 1,063 g (11,25 mmol) monokloreddiksyre og 630 mg (11,25 mmol) kaliumhydroksyd i 20 cm<3> vann. Reaksjonsblandingen oppvarmes til 60°C og pH holdes mellom 8 og 10 ved tilsetning av kaliumhydroksyd. Tilsetningen foregår i løpet av tre timer hvorunder 10 cm<3 >vann inneholdende 630 mg kaliumhydroksyd tilsettes. Etter en reaksjonstid på tre timer tilsettes 141 mg (1,5 mmol) kloreddiksyre og 84 mg (1,5 mmol) kaliumhydroksyd. (8.4 mmol) of potassium hydroxide. To this solution is added potassium monochloroacetate prepared from 1.063 g (11.25 mmol) monochloroacetic acid and 630 mg (11.25 mmol) potassium hydroxide in 20 cm<3> of water. The reaction mixture is heated to 60°C and the pH is kept between 8 and 10 by adding potassium hydroxide. The addition takes place over three hours, during which 10 cm<3> of water containing 630 mg of potassium hydroxide is added. After a reaction time of three hours, 141 mg (1.5 mmol) of chloroacetic acid and 84 mg (1.5 mmol) of potassium hydroxide are added.
Blandingen holdes deretter ved 60°C i to døgn. Etter av-kjøling og surgjøring til pH 2,6 (6N HC1) føres løsningen gjennom en kolonne med en sterk basisk harpiks IRA 958. Eluering med 100 cm<3> 10 % maur syre gir 7 00 mg av produktet. De gjennomstrømmede fraksjoner (produkt ikke tilbakeholdt) konsentreres og behandles på nytt på en identisk kolonne. Etter samme behandling oppnås 2,5 g av produktet (utbytte: 38,4%, Rf=0,65, silika/etanol/buffer/2/1) . The mixture is then kept at 60°C for two days. After cooling and acidifying to pH 2.6 (6N HCl), the solution is passed through a column with a strong basic resin IRA 958. Elution with 100 cm<3> 10% formic acid gives 700 mg of the product. The flow-through fractions (product not retained) are concentrated and reprocessed on an identical column. After the same treatment, 2.5 g of the product is obtained (yield: 38.4%, Rf=0.65, silica/ethanol/buffer/2/1).
NMR spektrum: 3H CH3 kjede (triplett 0,9 ppm), 10H CH2 kjede (multiplett ved 1,4 ppm), 15H CH2 og CH ring (multiplett ved 2,3 ppm), 8H CH2 COOH (singlett ved 3,9 ppm). NMR analyse ble gjennomført i D20. NMR spectrum: 3H CH3 chain (triplet 0.9 ppm), 10H CH2 chain (multiplet at 1.4 ppm), 15H CH2 and CH ring (multiplet at 2.3 ppm), 8H CH2 COOH (singlet at 3.9 ppm ). NMR analysis was carried out in D20.
EKSEMPEL 4 Fremstilling av gadoliniumkomplekset av 2-heksyl-1,4,7,10-tetraazacyklododekan-N,N', N'', EXAMPLE 4 Preparation of the gadolinium complex of 2-hexyl-1,4,7,10-tetraazacyclododecane-N,N', N'',
N'''-tetraeddiksyre. N'''-tetraacetic acid.
488,6 mg (1 mmol) av forbindelsen oppnådd i eksempel 3 og 181,3 mg (1 mekv. metall) gadoliniumoksyd ble suspendert i 40 cm<3> vann og oppvarmet ved 65°C i to døgn. Etter to timer er løsningen klar. Kompleksutviklingen måles under reaksjonen ved bestemmelse av fri gadolinium. Etter endt reaksjon filtreres løsningen gjennom et Millipore-filterpapir, avdampes deretter til tørrhet og krystalliseres fra etyleter. 550 mg av et hvitt faststoff oppnås (utbytte: 85,5 %, Rf=0,65, EtOH/buffer/2/1). 488.6 mg (1 mmol) of the compound obtained in example 3 and 181.3 mg (1 meq. metal) of gadolinium oxide were suspended in 40 cm<3> of water and heated at 65°C for two days. After two hours, the solution is ready. Complex development is measured during the reaction by determining free gadolinium. After completion of the reaction, the solution is filtered through a Millipore filter paper, then evaporated to dryness and crystallized from ethyl ether. 550 mg of a white solid is obtained (yield: 85.5%, Rf=0.65, EtOH/buffer/2/1).
EKSEMPEL 5 Fremstilling av gadoliniumkomplekset av 2-heksyl-1,4,7,10-tetraazacyklododekan-N, N' ,N'', EXAMPLE 5 Preparation of the gadolinium complex of 2-hexyl-1,4,7,10-tetraazacyclododecane-N,N',N'',
N'''-tetraeddiksyre (metylglukaminsalt). 488,6 mg (1 mmol) av forbindelsen oppnådd i eksempel 3 og 181,3 mg (1 mekv. metall) gadoliniumoksyd ble suspendert i 40 cm<3> vann og oppvarmet til 65°C i tolv timer. Metylglukamin tilsettes til den klare løsning for å bringe pH til 7,4. Det tilsettes ligander avhengig av resultatene av analysene. Endt kompleksdanneIse bekreftes ved fravær av Gd<3+> (bestemmelse ved xylenolorange) og av frie ligander (kompleksometrisk bestemmelse med kobber). Bestemmelse av totalt gadolinium i løs-ningen gjennomføres ved hjelp av atomemisjonsspektroskopi på et Spectrospan 4 Beckmann apparat. Rf=0,65, EtOH/buffer/2/1. N'''-tetraacetic acid (methylglucamine salt). 488.6 mg (1 mmol) of the compound obtained in Example 3 and 181.3 mg (1 meq. metal) of gadolinium oxide were suspended in 40 cm<3> of water and heated to 65°C for twelve hours. Methylglucamine is added to the clear solution to bring the pH to 7.4. Ligands are added depending on the results of the analyses. Ended complex formation is confirmed by the absence of Gd<3+> (determination with xylenol orange) and of free ligands (complexometric determination with copper). Determination of total gadolinium in the solution is carried out using atomic emission spectroscopy on a Spectrospan 4 Beckmann apparatus. Rf=0.65, EtOH/buffer/2/1.
EKSEMPEL 6 Fremstilling av 2-metyl-l,4,7,10-tetraazade-dokan-N,N',N'',N'''-tetraeddiksyre. EXAMPLE 6 Preparation of 2-methyl-1,4,7,10-tetraazade-docane-N,N',N'',N'''-tetraacetic acid.
a) Fremstilling av N,N'-ditosyl-1,2-diaminpropan. a) Preparation of N,N'-ditosyl-1,2-diaminopropane.
I en 1 1 trehalskolbe utstyrt med en magnetisk rører, et In a 1 1 three-necked flask fitted with a magnetic stirrer, et
termometer og et kontrollrør, oppløses 14,8 g 1,2-diaminpropan i 500 ml CH2C12 og 58 cm<3> Et3N. 80 g tosylklorid innføres i porsjoner i løpet av en time. Avkjøling på isbad er nødvendig for å opprettholde en temperatur på 2 0°C. thermometer and a control tube, dissolve 14.8 g of 1,2-diaminepropane in 500 ml of CH2C12 and 58 cm<3> Et3N. 80 g of tosyl chloride is introduced in portions over the course of an hour. Cooling in an ice bath is necessary to maintain a temperature of 20°C.
Reaksjonsblandingen omrøres deretter over natten ved romtemperatur . The reaction mixture is then stirred overnight at room temperature.
Reaksjonsblandingen overføres til 1 1 skilletrakt og vaskes deretter med 2 x 260 cm<3> vann. The reaction mixture is transferred to a 1 1 separatory funnel and then washed with 2 x 260 cm<3> of water.
Den organiske fase tørkes over Na2S04, avdampes til tørrhet og krystalliseres deretter fra isopropyleter. The organic phase is dried over Na 2 SO 4 , evaporated to dryness and then crystallized from isopropyl ether.
Oppnådd vekt = 66 g Achieved weight = 66 g
Utbytte = 86 % Yield = 86%
Smp. = 98/100°C Temp. = 98/100°C
NMR NMR
1 ppm dublett (3H) 3,1 ppm multiplett (1H) 1 ppm doublet (3H) 3.1 ppm multiplet (1H)
2,4 ppm singlett (6H) 5,5 ppm utskiftbar singlett (2H) 2.4 ppm singlet (6H) 5.5 ppm replaceable singlet (2H)
2,9 ppm dublett (2H) 7,1 til 7,8 ppm aromatiske forbindelser (8H) 2.9 ppm doublet (2H) 7.1 to 7.8 ppm aromatic compounds (8H)
TLC TLC
Si02 elueringsmiddel CH2C12 90 SiO 2 eluent CH 2 Cl 2 90
MeOH 10 Rf=0,75. MeOH 10 Rf=0.75.
b) Fremstilling av N,N'-ditosyl-bis(2-tosyloksyetyl)-etyl endi amin. b) Preparation of N,N'-ditosyl-bis(2-tosyloxyethyl)-ethyl endi amine.
I en 500 cm<3> trehalskolbe utstyrt med et termometer, et kontrollrør og en magnetisk rører avkjøles en løsning av 162 g tosylklorid i 300 ml pyridin til 0°C ved hjelp av et is-saltbad. In a 500 cm<3> three-necked flask equipped with a thermometer, a control tube and a magnetic stirrer, a solution of 162 g of tosyl chloride in 300 ml of pyridine is cooled to 0°C using an ice-salt bath.
29,6 g -av dette (2-hydroksyetyl)etylendiaminet tilsettes i porsjoner i løpet av to timer ved denne temperatur. Temperaturen må aldri overskride 5°C. Reaksjonsblandingen omrøres i fire timer ved denne temperatur, den får stå i 48 timer ved 6/8°C i kjøleskap og deretter i fire timer ved romtemperatur. 29.6 g of this (2-hydroxyethyl)ethylenediamine is added in portions over two hours at this temperature. The temperature must never exceed 5°C. The reaction mixture is stirred for four hours at this temperature, it is allowed to stand for 48 hours at 6/8°C in a refrigerator and then for four hours at room temperature.
Reaksjonsblandingen helles over ill isvann og 300 ml konsentrert HCl. Produktet ekstraheres med 500 ml CH2C12. Den organiske fase tørkes over Na2S04 og avdampes deretter til tørrhet. The reaction mixture is poured over ice water and 300 ml of concentrated HCl. The product is extracted with 500 ml of CH2C12. The organic phase is dried over Na 2 SO 4 and then evaporated to dryness.
Resten tas opp i 250 cm<3> etanol ved oppvarming. Produktet krystalliseres. Det avfUtreres på en glassfritte og tørkes ved 60°C i 48 timer. The residue is taken up in 250 cm<3> of ethanol by heating. The product crystallizes. It is dried on a glass frit and dried at 60°C for 48 hours.
Oppnådd vekt = 107,5 g Achieved weight = 107.5 g
Utbytte =70% Yield =70%
Smp. = 137/140°C Temp. = 137/140°C
NMR NMR
2,4 ppm singlett (12H) 2.4 ppm singlet (12H)
3,3 ppm singlett + triplett (8H) 3.3 ppm singlet + triplet (8H)
4,2 ppm triplett (4H) 4.2 ppm triplet (4H)
7,2 til 7,8 ppm multiplett (16H) 7.2 to 7.8 ppm multiplet (16H)
TLC TLC
Si02 plate elueringsmiddel toluen 80 Rf=0,6 SiO2 plate eluent toluene 80 Rf=0.6
aceton 20 acetone 20
c) Fremstilling av N,N' ,N'' ,N'''-tetratosyl-2-metyl-1,4,7,10-tetraazacyklododekan. c) Preparation of N,N',N'',N'''-tetratosyl-2-methyl-1,4,7,10-tetraazacyclododecane.
I en 1 1 trehalskolbe omrøres en løsning av 17,5 g N,N'-ditosyldiamin-1,2-propan i 500 ml tørr DMF i et kvarter ved omgivelsestemperatur. 33 g Cs2C03 knuses og tilsettes i suspensjon til denne løsningen. Denne suspensjon oppvarmes til 55°C ved hjelp av et oljebad i en inert atmosfære. In a 1 l three-necked flask, a solution of 17.5 g of N,N'-ditosyldiamine-1,2-propane in 500 ml of dry DMF is stirred for fifteen minutes at ambient temperature. 33 g of Cs2C03 are crushed and added in suspension to this solution. This suspension is heated to 55°C using an oil bath in an inert atmosphere.
En løsning av 35'g N,N'-ditosyl-bis(2-tosyloksyetyl)etylen-diamin i 200 cm<3> DMF tilsettes dråpevis ved denne temperatur i løpet av to timer. Etter end tilsetning fortsettes oppvarmingen i 48 timer. DMF fjernes deretter ved destillasjon i vakuum. Resten tas opp i en vann/CH2Cl2-blanding. A solution of 35 g of N,N'-ditosyl-bis(2-tosyloxyethyl)ethylenediamine in 200 cm<3> DMF is added dropwise at this temperature over the course of two hours. After the addition is complete, the heating is continued for 48 hours. DMF is then removed by distillation in vacuo. The remainder is taken up in a water/CH2Cl2 mixture.
Den organiske fase tørkes over Na2S04. Løsningsmiddelet fjernes ved destillasjon i en roterende evaporator. The organic phase is dried over Na2SO4. The solvent is removed by distillation in a rotary evaporator.
Resten oppvarmes og omrøres i 200 ml etylacetat. Det for-ventede produkt krystalliseres, avfiltreres og tørkes deretter ved 60°C i vakuum i 24 timer. The residue is heated and stirred in 200 ml of ethyl acetate. The expected product is crystallized, filtered off and then dried at 60°C in vacuum for 24 hours.
Oppnådd vekt = 22,5 g Achieved weight = 22.5 g
Utbytte =61% Yield =61%
Smp. = 274/275°C Temp. = 274/275°C
NMR NMR
1 ppm dubplett (2H) 1 ppm doublet (2H)
2,2 ppm singlett (12H) 2.2 ppm singlet (12H)
3 til 3,8 ppm multiplett (15H) 3 to 3.8 ppm multiplet (15H)
7,2 til 7,9 ppm multiplett (16H) aromatiske forbindelser 7.2 to 7.9 ppm multiplet (16H) aromatic compounds
TLC TLC
Si02 elueringsmiddel toluen = 80 SiO2 eluent toluene = 80
aceton = 20 Rf=0,56 acetone = 20 Rf=0.56
d) Fremstilling av 2-metyl-l,4,7,10-tetraazacyklododekan. d) Preparation of 2-methyl-1,4,7,10-tetraazacyclododecane.
I en 1 1 trehalskolbe utstyrt med et termometer, en argon-ballong og en mekanisk rører, oppvarmes en løsning av 72,5 g av forbindelsen oppnådd i c) i 300 ml 98 % H2S04 ved 100°C i 48 timer ved hjelp av et oljebad i en inert atmosfære. In a 1 L three-necked flask equipped with a thermometer, an argon balloon and a mechanical stirrer, a solution of 72.5 g of the compound obtained in c) in 300 ml of 98% H2SO4 is heated at 100°C for 48 hours using an oil bath in an inert atmosphere.
Reaksjonsblandingen avkjøles til omgivelsestemperatur og The reaction mixture is cooled to ambient temperature and
800 ml Et20, avkjølt til 0°C ved hjelp av et bad av etylen-glykol og tørris, tilsettes i løpet av en time. 800 ml of Et2O, cooled to 0°C using a bath of ethylene glycol and dry ice, is added over the course of one hour.
Det svært hygroskopiske sulfat presipiteres. Dette avfiltreres forsiktig på en glassfritte under nitrogen og oppløses deretter raskt i 200 ml vann. Denne løsning gjøres alkalisk (pelletter av NaOH) og ekstraheres deretter med 5 x 100 ml CH2C12. The highly hygroscopic sulfate is precipitated. This is carefully filtered off on a glass frit under nitrogen and then quickly dissolved in 200 ml of water. This solution is made alkaline (pellets of NaOH) and then extracted with 5 x 100 ml CH 2 Cl 2 .
De kombinerte organiske faser tørkes over Na2S04, avdampes deretter til tørrhet til å gi 15 g av et svært viskøst råprodukt som krystalliserer ved henstand. The combined organic phases are dried over Na 2 SO 4 , then evaporated to dryness to give 15 g of a highly viscous crude product which crystallizes on standing.
NMR NMR
CDClj 1,1 ppm dublett (2H) CDClj 1.1 ppm doublet (2H)
Spektrum i + D20 2,7 ppm 2 singletter som en multiplett Spectrum i + D20 2.7 ppm 2 singlets as a multiplet
(19H, 4 som er ombyttbare) (19H, 4 which are interchangeable)
TLC TLC
A1203 plate elueringsmiddel BuOH 50 Rf=0,8 A1203 plate eluent BuOH 50 Rf=0.8
H20 25 H20 25
AcOH 11 AcOH 11
e) Fremstilling av komplekset av 2-metyl-l,4,7,10-tetraaza-cyklododekan-N, N' ,N'',N#''-tetraeddsykrye med 2 KC1. e) Preparation of the complex of 2-methyl-1,4,7,10-tetraaza-cyclododecane-N,N',N'',N#''-tetraacetic acid with 2 KCl.
I en 250 ml trehalskolbe avkjøles en løsning av 34 g kloreddiksyre i 150 cm<3> vann til 10°C i et isbad. 20 g kaliumhydroksyd tilsettes ved denne temperatur for å nøytralisere syren. In a 250 ml three-necked flask, a solution of 34 g of chloroacetic acid in 150 cm<3> of water is cooled to 10°C in an ice bath. 20 g of potassium hydroxide is added at this temperature to neutralize the acid.
Forbindelsen oppnådd i d) oppløses deretter i denne løsning. Reaksjonsblandingen oppvarmes deretter til 65°C ved hjelp av et oljebad. The compound obtained in d) is then dissolved in this solution. The reaction mixture is then heated to 65°C using an oil bath.
En løsning av 20 g KOH i 50 cm<3> vann tilsettes forsiktig i løpet av seks timer ved denne temperatur mens pH holdes mellom 8 og 10. A solution of 20 g of KOH in 50 cm<3> of water is carefully added over six hours at this temperature while keeping the pH between 8 and 10.
Oppvarmingen fortsettes deretter i 72 timer, deretter sur-gjøres reaksjonsblandingen til pH 2,5 med konsentrert HCl. The heating is then continued for 72 hours, then the reaction mixture is acidified to pH 2.5 with concentrated HCl.
Komplekset presipiterer. Det avfiltreres på en glassfritte, renses med 50 cm<3> vann, og tørkes deretter ved 60°C i 18 timer i en ovn. The complex precipitates. It is filtered off on a glass frit, cleaned with 50 cm<3> of water, and then dried at 60°C for 18 hours in an oven.
Oppnådd vekt = 30 g Achieved weight = 30 g
Utbytte = 66 % Yield = 66%
Smp. > 300°C Temp. > 300°C
f) Rensing av 2-metyl-l,4,7,10-tetraazacyklododekan-1,4,7,10-tetraeddiksyre. 30 g av komplekset oppnådd i e) oppløses i nærvær av 150 cm<3 >IRA 958 harpiks, som var nylaget på forhånd. f) Purification of 2-methyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. 30 g of the complex obtained in e) is dissolved in the presence of 150 cm<3 >IRA 958 resin, which was freshly prepared beforehand.
Etter oppløsning av komplekset påføres denne suspensjon øverst i en kolonne inneholdende 150 cm<3> IRA 958 harpiks. After dissolution of the complex, this suspension is applied to the top of a column containing 150 cm<3> of IRA 958 resin.
Elueringen gjennomføres med en 5 % eddiksyreløsning i vann. The elution is carried out with a 5% acetic acid solution in water.
Fraksjonene som inneholdt det forvendtede rene produkt avdampes til tørrhet for å fjerne eddiksyren fullstendig. The fractions containing the precipitated pure product are evaporated to dryness to completely remove the acetic acid.
Oppnådd vekt = 18,4 g Achieved weight = 18.4 g
Utbytte = 89 % Yield = 89%
Surhet = 100,3 % (4 ekvivalenter) tritrert med 0,1 M Acidity = 100.3% (4 equivalents) titrated with 0.1 M
NAOH NAOH
TLC TLC
Si02 elueringsmiddel AcOEt 12 Rf=0,36 SiO2 eluent AcOEt 12 Rf=0.36
Isopropanol 35 Isopropanol 35
NH3, H2 30 NH3, H2 30
FAB massespektrum : massetopp ved M + 1 = 419. FAB mass spectrum: mass peak at M + 1 = 419.
EKSEMPEL 7 Fremstilling av en løsning av gadoliniumkomplekset av 2-metyl-l,4,7,10-tetraazacyklodode-kan-N, N' ,N' ',N'''-tetraeddiksyre (metylglukaminsalt). EXAMPLE 7 Preparation of a solution of the gadolinium complex of 2-methyl-1,4,7,10-tetraazacyclododocan-N,N',N'',N'''-tetraacetic acid (methylglucamine salt).
21 g (50 mmol) av forbindelsen oppnådd i eksempel 6 og 9,05 g (25 mmol) gadoliniumoksyd oppløses i 50 ml vann som er destillert to ganger og avluftet ved 70°C. Etter en time er oppløsningen fullstendig og pH er nær 3. Etter avkjøling justeres pH til 7,3 med metylglukamin. Løsningen innstilles til 100 ml og filtreres gjennom en 0,22 Jj.m Millipore-membran. En løsning med et gadoliniuminnhold på 0,5 mol/l oppnås. Denne løsning har en viskositet ved 20°C på mindre enn 4 mPa.s. 21 g (50 mmol) of the compound obtained in example 6 and 9.05 g (25 mmol) of gadolinium oxide are dissolved in 50 ml of water which has been distilled twice and deaerated at 70°C. After one hour, the solution is complete and the pH is close to 3. After cooling, the pH is adjusted to 7.3 with methylglucamine. The solution is adjusted to 100 ml and filtered through a 0.22 µm Millipore membrane. A solution with a gadolinium content of 0.5 mol/l is obtained. This solution has a viscosity at 20°C of less than 4 mPa.s.
(Fri Gd ikke påvist). (Free Gd not proven).
EKSEMPEL 8 2-hydroksymetyl-1,4,7,10-tetraazacykododekan-4,7,10-trieddiksyre. EXAMPLE 8 2-Hydroxymethyl-1,4,7,10-tetraazacycododecane-4,7,10-triacetic acid.
a) Fremstilling av N,N</->ditosyl-2,3-diaminpropionsyre. a) Preparation of N,N</->ditosyl-2,3-diaminepropionic acid.
Til en løsning av 46 g na tr iumhydr oksyd i 500 cm<3> vann tilsettes 40 g av monohydrokloridet av 2,3-diaminpropionsyre med kraftig omrøring. 200 cm<3> etyleter tilsettes etterfulgt av 110,5 g tosylklorid i porsjoner i løpet av en time. Om-røringen fortsetter i tolv timer, og det dannede presipitat avfUtreres, vaskes med vann og etyleter. Faststoffet som oppnås suspenderes ill vann og surgjøres med 6N HC1. Etter filtrering og vasking med vann og etyleter tørkes faststoffet i 24 timer ved 60°C i vakuum. To a solution of 46 g of sodium hydroxide in 500 cm<3> of water, 40 g of the monohydrochloride of 2,3-diaminepropionic acid is added with vigorous stirring. 200 cm<3> of ethyl ether are added followed by 110.5 g of tosyl chloride in portions over the course of one hour. The stirring continues for twelve hours, and the precipitate formed is filtered off, washed with water and ethyl ether. The solid obtained is suspended in water and acidified with 6N HCl. After filtering and washing with water and ethyl ether, the solid is dried for 24 hours at 60°C in a vacuum.
Oppnådd vekt = 76 g Achieved weight = 76 g
Utbytte = 65% Yield = 65%
Smp. = 200-201°C Temp. = 200-201°C
TLC: Si02 CH2C12 80/MeOH 20 TLC: SiO 2 CH 2 Cl 2 80/MeOH 20
Rf= 0,5 Rf = 0.5
NMR NMR
- 2,4 ppm singlett 6H (CH3 i tosylgruppen) - 2.4 ppm singlet 6H (CH3 in the tosyl group)
- 2,8 ppm multiplett 3H (CH2, CH i diaminkjeden) - 2.8 ppm multiplet 3H (CH2, CH in the diamine chain)
- 3,5 til 5 ppm utstrakt multiplett 3H ombyttbar med D20 - 3.5 to 5 ppm extended multiplet 3H exchangeable with D20
- 7,2 til 7,8 ppm multiplett 8H aromatiske forbindelser. - 7.2 to 7.8 ppm multiplet 8H aromatic compounds.
b) Fremstilling av N,N' -ditosyl-2,3-diaminpropanol. b) Preparation of N,N'-ditosyl-2,3-diaminepropanol.
I en 2 1 trehalskolbe omrøres en suspensjon av 40 g av In a 2 1 wooden-necked flask, a suspension of 40 g of
forbindelsen oppnådd i b) i 600 cm<3> THF ved 20°C i en inert og vannfri atmosfære (argon). the compound obtained in b) in 600 cm<3> THF at 20°C in an inert and anhydrous atmosphere (argon).
En løsning av 500 ml IM BH3:THF tilsettes i en inert atmosfære i løpet av en halv time. Temperaturen i reaksjonsblandingen økes til 3 0°C. Omrøringen fortsetter i 48 timer. Hydrolyse gjennomføres forsiktig med 20 ml vann. THF fjernes ved destillasjon i vakuum. Resten ekstraheres med en vann/eter-blanding. Den organiske fase vaskes med vann, tørkes over Na2S04 og avdampes deretter til tørrhet. Resten males med isopropyleter inntil krystallisasjon. Etter filtrering og tørking oppnås 35 g produkt. A solution of 500 ml IM BH3:THF is added in an inert atmosphere over half an hour. The temperature in the reaction mixture is increased to 30°C. Stirring continues for 48 hours. Hydrolysis is carried out carefully with 20 ml of water. THF is removed by distillation in vacuo. The residue is extracted with a water/ether mixture. The organic phase is washed with water, dried over Na 2 SO 4 and then evaporated to dryness. The residue is ground with isopropyl ether until crystallization. After filtration and drying, 35 g of product is obtained.
Utbytte: 90 % Yield: 90%
Smp.: 126-127°C M.p.: 126-127°C
TLC: Si02 CH2C12 90/MeOH 10 TLC: SiO 2 CH 2 Cl 2 90/MeOH 10
Rf: 0,6 Rf: 0.6
NMR NMR
- 2,7 ppm singlett "CH3" av tosyl (6H) - 2.7 ppm singlet "CH3" of tosyl (6H)
- 3 til 3,7 ppm multiplett (7H, hvorav 2 er ombyttbare) - 3 to 3.7 ppm multiplet (7H, of which 2 are interchangeable)
- 6,9 ppm triplett, ombyttbar alkoholisk OH (1H) - 6.9 ppm triplet, exchangeable alcoholic OH (1H)
- 7,3 til 7,9 ppm multiplett aromatiske forbindelser (8H) - 7.3 to 7.9 ppm multiplet aromatic compounds (8H)
c) Fremstilling av N,N' ,N'' #N'''-tetratosyl-2-hydroksymetyl-1,4,7,10-tetraazacyklododekan. c) Preparation of N,N' ,N'' #N'''-tetratosyl-2-hydroxymethyl-1,4,7,10-tetraazacyclododecane.
I en 2 1 trehalskolbe under argon oppløses 35 g av forbindelsen oppnådd ib) ill vannfri DMF. Deretter tilsettes 58,6 g vannfri Cs2C03. In a 2 l three-necked flask under argon, 35 g of the compound obtained in ib) are dissolved in anhydrous DMF. 58.6 g of anhydrous Cs2C03 are then added.
Denne suspensjon omrøres i en time ved omgivelsestemperatur, og oppvarmes deretter til 65°C ved hjelp av et oljebad. En løsning inneholdende 69 g N,N'-ditosyl-bis(2-tosyloksyetyl)-etylendiamin i 600 cm<3> vannfri DMF tilsettes dråpevis ved denne temperatur i løpet av seks timer. Oppvarming ved 65°C opprettholdes over natten. DMF fjernes ved destillasjon i vakuum. Resten tas opp i en blanding av 400 ml vann og 400 cm<3> diklormetan. Den organiske fase dekanteres, vaskes med 200 cm<3> vann, tørkes over Na2S04 og avdampes deretter til tørrhet. Restoljen oppløses ved 80°C i 200 cm<3> toluen, og oppbevares deretter i kjøleskap i 48 timer for krystallisasjon. 24 g produkt oppnås. This suspension is stirred for one hour at ambient temperature, and then heated to 65°C using an oil bath. A solution containing 69 g of N,N'-ditosyl-bis(2-tosyloxyethyl)-ethylenediamine in 600 cm<3> of anhydrous DMF is added dropwise at this temperature over the course of six hours. Heating at 65°C is maintained overnight. DMF is removed by distillation in vacuum. The residue is taken up in a mixture of 400 ml of water and 400 cm<3> of dichloromethane. The organic phase is decanted, washed with 200 cm<3> of water, dried over Na 2 SO 4 and then evaporated to dryness. The residual oil is dissolved at 80°C in 200 cm<3> toluene, and then stored in a refrigerator for 48 hours for crystallization. 24 g of product is obtained.
Utbytte: 32 % Yield: 32%
Smp.: 143-145°C M.p.: 143-145°C
TLC: Si02 CH2C12 90/AcOEt 10 TLC: SiO 2 CH 2 Cl 2 90/AcOEt 10
Rf=0,5Rf=0.5
NMR NMR
2,4 ppm singlett 12H CH3 tosyl 2.4 ppm singlet 12H CH3 tosyl
3,2 til 4,1 ppm multiplett 17H CH2 ring + CH2-OH 3.2 to 4.1 ppm multiplet 17H CH2 ring + CH2-OH
7,2 til 8,1 ppm multiplett 16H aromatiske forbindelser 7.2 to 8.1 ppm multiplet 16H aromatic compounds
d) Fremstilling av 2-hydroksymetyl-l/4,7,10-tetraazacyklo-dodekan. 20 g av forbindelsen oppnådd i c) oppløses i 100 cm<3> 98 % H2S04. Denne løsning oppvarmes til 100°C i 48 timer i en inert atmosfære. Reaksjonsblandingen avkjøles og tilsettes deretter dråpevis til 1 1 etyleter avkjølt ved hjelp av et tørris/ace-tonbad. Presipitatet av sulfatet av aminet frafiltreres på en glassfritte og vaskes deretter med etyleter. Faststoffet oppløses umiddelbart i 2 00 cm<3> vann og løsningen justeres til pH 12 med NaOH og avdampes til tørrhet. Etter tørking av den faste rest i vakuum i nærvær av P205, ekstraheres produktet med 2 x 100 cm<3> THF med tilbakeløp. Avdamping av de oppnådde fraksjoner etter ekstråksjon ga en fargeløs olje. d) Preparation of 2-hydroxymethyl-1/4,7,10-tetraazacyclododecane. 20 g of the compound obtained in c) are dissolved in 100 cm<3> 98% H 2 SO 4 . This solution is heated to 100°C for 48 hours in an inert atmosphere. The reaction mixture is cooled and then added dropwise to 1 1 of ethyl ether cooled using a dry ice/acetone bath. The precipitate of the sulphate of the amine is filtered off on a glass frit and then washed with ethyl ether. The solid is immediately dissolved in 200 cm<3> of water and the solution is adjusted to pH 12 with NaOH and evaporated to dryness. After drying the solid residue in vacuo in the presence of P 2 O 5 , the product is extracted with 2 x 100 cm<3> THF under reflux. Evaporation of the obtained fractions after extraction gave a colorless oil.
Oppnådd vekt: 4,5 g base Achieved weight: 4.5 g base
Utbytte: 90 % Yield: 90%
TLF: A1203 BuOH 50/vann 2 5/AcOH 11 TEL: A1203 BuOH 50/water 2 5/AcOH 11
Rf: 0,8 Rf: 0.8
NMR (CDCL3 spektrum) NMR (CDCL3 spectrum)
2,8 ppm singlett (17H) + triplett 2.8 ppm singlet (17H) + triplet
3,8 ppm ombyttbar singlett (5H) 3.8ppm Interchangeable Singlet (5H)
e) Fremstilling av 2-hydroksymetyl-l,4,7,10-tetraazacyklo-dodekan-4,7,10-trieddiksyre. e) Preparation of 2-hydroxymethyl-1,4,7,10-tetraazacyclododecane-4,7,10-triacetic acid.
I en 250 cm<3> trehalskolbe utstyrt med en varmeelement/magnetisk rører, en temperaturføler og en pH elektrode som er for-bundet med et analogt pH meter og et system for tilsetning av reagens i korrelasjon med pH i mediumet, nøytraliseres en løsning av 8,5 g av forbindelsen oppnådd id), 15,8 g 2-kloreddiksyre og 100 ml vann til pH lik 9,5 ved hjelp av en løsning av 15,8 g kaliumhydroksyd i 50 cm<3> vann. Reaksjonsblandingen oppvarmes deretter ved 50°C ved hjelp av et oljebad i 72 timer. pH justeres kontinuerlig til 9,5 ved tilsetning av en løsning av kaliumhydroksyd. Blandingen avkjøles, surgjøres til pH lik 5, fortynnes til 500 cm<3> og påføres på en kolonne av 500 cm<3> av den sterkt basiske anionbytterharpiksen IRA 958, som er regenerert på forhånd. Alkyleringsproduktene binder seg til harpiksen. Denne renses med vann og elueres deretter med fraksjoner av 5 % eddiksyre. Fraksjonene avdampes til tørrhet. Resten er et urent pulver som renses på en preparativ HPLC kolonne med diameter 40 fylt med RP.18-podet silika. In a 250 cm<3> wooden-necked flask equipped with a heating element/magnetic stirrer, a temperature sensor and a pH electrode which is connected to an analogue pH meter and a system for adding reagent in correlation with the pH in the medium, a solution of 8.5 g of the compound obtained id), 15.8 g of 2-chloroacetic acid and 100 ml of water to pH equal to 9.5 using a solution of 15.8 g of potassium hydroxide in 50 cm<3> of water. The reaction mixture is then heated at 50°C using an oil bath for 72 hours. The pH is continuously adjusted to 9.5 by adding a solution of potassium hydroxide. The mixture is cooled, acidified to pH equal to 5, diluted to 500 cm<3> and applied to a column of 500 cm<3> of the strongly basic anion exchange resin IRA 958, which has been regenerated in advance. The alkylation products bind to the resin. This is cleaned with water and then eluted with fractions of 5% acetic acid. The fractions are evaporated to dryness. The residue is an impure powder that is purified on a preparative HPLC column with diameter 40 filled with RP.18-grafted silica.
Oppnådd vekt: 3,5 g rent produkt Weight achieved: 3.5 g pure product
Utbytte: 22 % Yield: 22%
Smp.: 142-144°C M.p.: 142-144°C
TLC: Si02 AcOEt 12/Isopropanol 35/NH4OH 30 TLC: SiO2 AcOEt 12/Isopropanol 35/NH4OH 30
Rf: 0,35 Rf: 0.35
Surhet: 198,7 % (2 bølger) Acidity: 198.7% (2 waves)
Titrering med 0,1 M NaOH - korrigert for H20 Titration with 0.1 M NaOH - corrected for H 2 O
FAB massespektrum: topp ved M + 1 = 377 FAB mass spectrum: peak at M + 1 = 377
EKSEMPEL 9 Fremstilling av en løsning av gadoliniumkomplekset av 2-hydroksymetyl-l,4,7,10-tetraaza-cyklododekan-4,7,10-trieddiksyre. EXAMPLE 9 Preparation of a solution of the gadolinium complex of 2-hydroxymethyl-1,4,7,10-tetraaza-cyclododecane-4,7,10-triacetic acid.
En suspensjon av 11,05 g 2-hydroksymetyl-l,4,7,10-tetraaza-cyklododekan-4,7,10-trieddiksyre og 5,07 g gadoliniumoksyd i vann destillert to ganger, oppvarmes ved 80°C i en time. Etter avkjøling justeres pH til 7,3 ved tilsetning av natriumhydroksyd og volumet innstilles til 100 ml. Bestemmelsen av totalt gadolinium gjennomføres ved atomemisjonsspektroskopi (0,2 M"1) . A suspension of 11.05 g of 2-hydroxymethyl-1,4,7,10-tetraaza-cyclododecane-4,7,10-triacetic acid and 5.07 g of gadolinium oxide in twice-distilled water is heated at 80°C for one hour . After cooling, the pH is adjusted to 7.3 by adding sodium hydroxide and the volume is set to 100 ml. The determination of total gadolinium is carried out by atomic emission spectroscopy (0.2 M"1).
EKSEMPEL 10 Fremstilling av 2-hydroksymetyl-l,4,7,10-t etraaz acyklododekan-1,4,7,10-tetraeddiksyre. EXAMPLE 10 Preparation of 2-hydroxymethyl-1,4,7,10-tetraaz acyclododecane-1,4,7,10-tetraacetic acid.
I en reaktor på 50 cm<3> utstyrt med en magnetisk rører oppvarmes en løsning av 0,7 g 2-hydroksymetyl-l,4,7,10-tetraaza-cyklododekan-4,7,10-trieddiksyre og 0,2 g kloreddiksyre i 15 cm<3> vann ved 70°C. In a 50 cm<3> reactor equipped with a magnetic stirrer, heat a solution of 0.7 g of 2-hydroxymethyl-1,4,7,10-tetraaza-cyclododecane-4,7,10-triacetic acid and 0.2 g chloroacetic acid in 15 cm<3> of water at 70°C.
pH bringes til 10,5 ved hjelp av en løsning av kaliumhydroksyd og holdes ved denne verdi i 48 timer ved 70°C. The pH is brought to 10.5 using a solution of potassium hydroxide and maintained at this value for 48 hours at 70°C.
Etter endt reaksjon bringes pH til 5. Deretter påføres løs-ningen på en IRA 958 harpiks. After the reaction has ended, the pH is brought to 5. The solution is then applied to an IRA 958 resin.
Liganden kromatograferes på harpiksen ved eluering med 5 % eddiksyre. The ligand is chromatographed on the resin by elution with 5% acetic acid.
Etter avdamping til tørrhet, renses produktet ved preparativ HPLC (RP18-podet silika). After evaporation to dryness, the product is purified by preparative HPLC (RP18-grafted silica).
0,15 g ligand oppnås således i et utbytte på 18%. 0.15 g of ligand is thus obtained in a yield of 18%.
TLC (silika) elueringsmiddel etylacetat 12 TLC (silica) eluent ethyl acetate 12
Isopropanol 35 Rf=0,25 Isopropanol 35 Rf=0.25
NH3, H20 30 NH3, H20 30
FAB massespektrum: topp ved M + 1 = 435. FAB mass spectrum: peak at M + 1 = 435.
EKSEMPEL 11 Fremstilling av 2-(2-hydroksymetyl)-1,4,7,10-tetraazacyklododekan-N, N',N'',N'''-tetraeddik-syre. EXAMPLE 11 Preparation of 2-(2-hydroxymethyl)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid.
Denne liganden fremstilles i henhold til prosedyren som beskrevet i eksempel 8 og 10 for syntese av 2-hydroksymetyl-1,4,7,10-tetraazacyklododekan-N,N',N'',N'''-tetraeddiksyre med utgangspunkt i 3,4-diaminbutansyre (S. Kasina et al., J. Med. Chem., 29, 1933, 1986). This ligand is prepared according to the procedure described in examples 8 and 10 for the synthesis of 2-hydroxymethyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid starting from 3 ,4-diaminobutanoic acid (S. Kasina et al., J. Med. Chem., 29, 1933, 1986).
EKSEMPEL 12 Fremstilling av 2-metyl-l/4,7,10#13-pentaaza-cyklopentadekan-4,7,10,13-tetraeddiksyre (produkt 12a) og 2-metyl-l,4,7,10,13-pentaazacyklo-pentadekan-1,4,7,10,13-pentaeddiksyre (produkt 12b). a) Fremstilling av 1,4,7,10,13-pentatosyl-2-metyl-1,4,7,10,13-pentaazacyklopentadekan. EXAMPLE 12 Preparation of 2-methyl-1/4,7,10#13-pentaaza-cyclopentadecane-4,7,10,13-tetraacetic acid (product 12a) and 2-methyl-1,4,7,10,13- pentaazacyclopentadecane-1,4,7,10,13-pentaacetic acid (product 12b). a) Preparation of 1,4,7,10,13-pentatosyl-2-methyl-1,4,7,10,13-pentazacyclopentadecane.
35,7 g (0,093 mol) N,N'-ditosyl-1,2-diaminpropan, 75,7 g cesiumkarbonat (0,23 mol) og 800 ml DMF innføres i en 2 1 trehalskolbe utstyrt med en kjøler og en mekanisk rører. Blandingen plasseres under argon og oppvarmes ved 75°C. 35.7 g (0.093 mol) of N,N'-ditosyl-1,2-diaminopropane, 75.7 g of cesium carbonate (0.23 mol) and 800 ml of DMF are introduced into a 2 L three-necked flask equipped with a condenser and a mechanical stirrer . The mixture is placed under argon and heated at 75°C.
En løsning av 83 g (0,012 mol) 1,ll-mesyloksy-3,6,9-tritosyl-3, 6, 9-triazaundekan, syntetisert i henhold til Richman og Atkins, Organic Synthesis 58, s. 86, i 700 ml DMF tilsettes i. løpet av 4 timer ved 75°C. A solution of 83 g (0.012 mol) of 1,11-mesyloxy-3,6,9-tritosyl-3, 6, 9-triazaundecane, synthesized according to Richman and Atkins, Organic Synthesis 58, p. 86, in 700 ml DMF is added over the course of 4 hours at 75°C.
Reaksjonsblandingen holdes ved 75°C i 48 timer, filtreres deretter og filtratet avdampes til tørrhet. The reaction mixture is kept at 75°C for 48 hours, then filtered and the filtrate is evaporated to dryness.
Resten tas opp i 700 ml etanol, faststoffet frafiltreres og tas deretter opp i 800 ml toluen med oppvarming. The residue is taken up in 700 ml of ethanol, the solid is filtered off and then taken up in 800 ml of toluene with heating.
Faststoffet frafiltreres ved romtemperatur og tørkes deretter ved 60°C. The solid is filtered off at room temperature and then dried at 60°C.
Oppnådd vekt: 45,4 g Achieved weight: 45.4 g
Utbytte: 49 % Yield: 49%
Analyse: TLC: Si02 60 F 254 Merck Analysis: TLC: SiO 2 60 F 254 Merck
Elueringsmiddel CH2Cl2/aceton 98,2 Rf: 0,45 Eluent CH2Cl2/acetone 98.2 Rf: 0.45
Massespektrum Mass spectrum
DCI metode (NH3) DCI method (NH3)
Massetopp ved 999. Mass peak at 999.
b) Fremstilling av 2-metyl-l,4,7,10,13-pentaazacyklo-pentadekan . b) Preparation of 2-methyl-1,4,7,10,13-pentazacyclopentadecane.
44 g (0,044 mol) av forbindelsen oppnådd i a) holdes i 44 g (0.044 mol) of the compound obtained in a) is kept in
72 timer ved 100°C i 130 ml konsentrert svovelsyre. 72 hours at 100°C in 130 ml concentrated sulfuric acid.
Etter avkjøling, helles reaksjonsblandingen inn i en blanding av 250 ml etyleter og 2 50 ml etanol ved 0°C. After cooling, the reaction mixture is poured into a mixture of 250 ml of ethyl ether and 250 ml of ethanol at 0°C.
Faststoffet frafiltreres, oppløses deretter i 250 ml vann og behandles med karbonblack. Løsningen gjøres alkalisk med cesiumhydroksyd og ekstraheres deretter med CH2C12. Den organiske løsning tørkes over Na2S04 og avdampes til tørrhet. Aminet som således oppnås kan anvendes som sådan eller i form av dets hydroklorid. The solid is filtered off, then dissolved in 250 ml of water and treated with carbon black. The solution is made alkaline with cesium hydroxide and then extracted with CH2C12. The organic solution is dried over Na2SO4 and evaporated to dryness. The amine thus obtained can be used as such or in the form of its hydrochloride.
Oppnådd vekt: M = 8,4 g som fri base Weight achieved: M = 8.4 g as free base
M = 13,2 g som 5 HC1 M = 13.2 g as 5 HCl
Utbytte: 72,8 % Yield: 72.8%
Analyse av hydrokloridet: Analysis of the hydrochloride:
TLC: Al203 F 254 Merck TLC: Al 2 O 3 F 254 Merck
Elueringsmiddel: etanol/isopropylamin 80/20 Eluent: ethanol/isopropylamine 80/20
Fremkaller: jod Rf: 0,85 Developer: iodine Rf: 0.85
NMR: 1,7 ppm 3H CH3NMR: 1.7 ppm 3 H CH 3
3,7 ppm 19H CH2 og CH. 3.7 ppm 19H CH2 and CH.
c) Fremstilling av 2-metyl-l,4,7,10,13-pentaazacyklopenta-dekan-4,7,10,13-tetraeddiksyre (produkt 12a) og 2-metyl-1,4,7,10,13-pentaazacyklopentadekan-l,4,7,10,13-penta-eddiksyre (produkt 12b). c) Preparation of 2-methyl-1,4,7,10,13-pentazacyclopentadecane-4,7,10,13-tetraacetic acid (product 12a) and 2-methyl-1,4,7,10,13- pentaazacyclopentadecane-1,4,7,10,13-penta-acetic acid (product 12b).
I en 500 ml trehalskolbe nøytraliseres en løsning av 25,7 g (0,27 mol) kloreddiksyre 50 ml vann til pH 5 ved en temperatur In a 500 ml three-necked flask, a solution of 25.7 g (0.27 mol) of chloroacetic acid in 50 ml of water is neutralized to pH 5 at a temperature
< 10°C ved hjelp av 5 M kaliumhydroksyd. < 10°C using 5 M potassium hydroxide.
10 g av forbindelsen oppnådd i b) (10,043 mmol) oppløst i 10 g of the compound obtained in b) (10.043 mmol) dissolved in
20 ml vann tilsettes til løsningen. Blandingen oppvarmes ved 55°C og 50 ml 5 M kaliumhydroksyd tilsettes i løpet av 48 timer for å holde en pH på 8,5-9,5. Etter endt tilsetning fortsetter oppvarmingen over natten. Reaksjonsblandingen avkjøles og surgjøres til pH 3. Løsningen påføres deretter på 200 ml DOWEX 50 W harpiks. Eluering av harpiksen med 1 1 av en 1 M ammoniakkløsning gir 20 g urent produkt. Det urene produkt oppløses i 150 ml vann og påføres på 250 ml IRA 958 harpiks. Harpiksen vaskes med vann/ og elueres deretter med 2 1 0,1 M eddiksyre, etterfulgt av 2 1 0,8 M eddiksyre. 9 g av urent produkt 12a oppnås ved avdamping av 0,1 M eddiksyre. 2,5 g av urent produkt 12b oppnås ved avdamping av 0,8 M eddiksyre. 20 ml of water is added to the solution. The mixture is heated at 55°C and 50 ml of 5 M potassium hydroxide is added over 48 hours to maintain a pH of 8.5-9.5. After the addition is complete, the heating continues overnight. The reaction mixture is cooled and acidified to pH 3. The solution is then applied to 200 ml of DOWEX 50 W resin. Elution of the resin with 1 L of a 1 M ammonia solution gives 20 g of impure product. The impure product is dissolved in 150 ml of water and applied to 250 ml of IRA 958 resin. The resin is washed with water/ and then eluted with 2 1 0.1 M acetic acid, followed by 2 1 0.8 M acetic acid. 9 g of impure product 12a is obtained by evaporation of 0.1 M acetic acid. 2.5 g of impure product 12b is obtained by evaporation of 0.8 M acetic acid.
Produktene 12a og 12b renses deretter ved preparativ HPLC på RP18-silika. The products 12a and 12b are then purified by preparative HPLC on RP18 silica.
Oppnådd produkt: produkt 12a: M = 5 g Product obtained: product 12a: M = 5 g
produkt 12b: M = 1,1 g product 12b: M = 1.1 g
Utbytte: 30% Yield: 30%
Analyser: Analyze:
TLC: Si02 60 F 254 Merck TLC: SiO 2 60 F 254 Merck
Elueringsmiddel: etylacetat/isopropanol/NH3 (30 %)/12/35/30 Fremkaller: jod Eluent: ethyl acetate/isopropanol/NH3 (30%)/12/35/30 Developer: iodine
Produkt 12a Rf: 0,4 Product 12a Rf: 0.4
Produkt 12b Rf: 0,27 Product 12b Rf: 0.27
Vannanalyser: Water analyses:
Produkt 12a: KF: 1,8% Product 12a: KF: 1.8%
Produkt 12b: KF: 2,8% Product 12b: KF: 2.8%
Surhetsanalyser ved hjelp av 0,1 M NaOH Acidity analyzes using 0.1 M NaOH
Produkt 12a: To surhetsanalyser 98,6% og 100,6% titrervæske: 99,6% Product 12a: Two acidity analyzes 98.6% and 100.6% titration liquid: 99.6%
Produkt 12b: Tre surhetsanalyser 199,2 % og 92,4 % Product 12b: Three acidity analyzes 199.2% and 92.4%
titrervæske: 97,3% titration liquid: 97.3%
FAB massespektrum: FAB mass spectrum:
12a topp ved M + 1 = 462 12a peak at M + 1 = 462
12b topp ved M + 1 = 52 0 12b peak at M + 1 = 52 0
Claims (12)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8705288A FR2614020B1 (en) | 1987-04-14 | 1987-04-14 | NOVEL NITROGEN CYCLIC LIGANDS, METAL COMPLEXES FORMED BY SUCH LIGANDS, DIAGNOSTIC COMPOSITIONS CONTAINING THESE COMPLEXES AND PROCESS FOR PREPARING LIGANDS. |
Publications (4)
Publication Number | Publication Date |
---|---|
NO881567D0 NO881567D0 (en) | 1988-04-12 |
NO881567L NO881567L (en) | 1988-10-17 |
NO176839B true NO176839B (en) | 1995-02-27 |
NO176839C NO176839C (en) | 1995-06-14 |
Family
ID=9350106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO881567A NO176839C (en) | 1987-04-14 | 1988-04-12 | Ligands and methods for their preparation, metal complexes formed with these ligands, as well as diagnostic composition and X-ray contrast agent comprising the above metal complexes |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0287465B1 (en) |
JP (1) | JP2675058B2 (en) |
KR (1) | KR880012572A (en) |
CN (1) | CN1022411C (en) |
AT (1) | ATE85052T1 (en) |
AU (1) | AU606146B2 (en) |
DD (1) | DD293113A5 (en) |
DE (1) | DE3877799T2 (en) |
DK (1) | DK170946B1 (en) |
ES (1) | ES2053779T3 (en) |
FI (1) | FI93830C (en) |
FR (1) | FR2614020B1 (en) |
GR (1) | GR3007495T3 (en) |
HR (1) | HRP920514A2 (en) |
HU (1) | HU198501B (en) |
IE (1) | IE62582B1 (en) |
IL (1) | IL86059A (en) |
NO (1) | NO176839C (en) |
PT (1) | PT87216B (en) |
SI (1) | SI8810742A (en) |
YU (1) | YU46691B (en) |
ZA (1) | ZA882552B (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5059412A (en) * | 1984-06-04 | 1991-10-22 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors |
US5064633A (en) * | 1984-06-04 | 1991-11-12 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes, their formulations and use |
US5362476A (en) * | 1984-10-18 | 1994-11-08 | Board Of Regents, The University Of Texas System | Alkyl phosphonate polyazamacrocyclic cheates for MRI |
US5316757A (en) * | 1984-10-18 | 1994-05-31 | Board Of Regents, The University Of Texas System | Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups |
FR2637895B1 (en) * | 1988-10-14 | 1992-11-06 | Guerbet Sa | NOVEL NITROGEN CYCLIC LIGANDS, METAL COMPLEXES FORMED BY THESE LIGANDS, DIAGNOSTIC COMPOSITIONS CONTAINING THESE COMPLEXES AND PROCESS FOR THE PREPARATION OF LIGANDS |
US5531978A (en) * | 1987-07-16 | 1996-07-02 | Nycomed Imaging As | Aminopolycarboxylic acids and derivatives thereof |
ES2033433T3 (en) * | 1987-07-16 | 1993-03-16 | Nycomed As | PROCEDURE TO PREPARE AMINOPOLICARBOXILIC ACIDS AND THEIR DERIVATIVES. |
AU617338B2 (en) * | 1987-07-16 | 1991-11-28 | Nycomed As | Aminopolycarboxylic acids and derivatives thereof |
GB8719042D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
RU2059642C1 (en) * | 1987-12-24 | 1996-05-10 | Бракко Индустрия Кимика С.п.А | Gadolinium chelates and a method of their synthesis |
GB8801646D0 (en) * | 1988-01-26 | 1988-02-24 | Nycomed As | Chemical compounds |
ES2116291T3 (en) * | 1989-10-23 | 1998-07-16 | Nycomed Salutar Inc | CHELATING AGENTS OF METALS IN MULTIPLE SITES. |
US5446145A (en) * | 1990-01-19 | 1995-08-29 | Nycomed Salutar, Inc. | Polychelant compounds |
GB8923843D0 (en) * | 1989-10-23 | 1989-12-13 | Salutar Inc | Compounds |
US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
AU6709390A (en) * | 1989-12-22 | 1991-06-27 | E.R. Squibb & Sons, Inc. | 10-(2'-hydroxy-3'-polyoxaalkyl)-1,4,7-tris-carboxymethyl -1,4,7,10-tetraazacyclododecane |
AU625529B2 (en) * | 1989-12-22 | 1992-07-16 | E.R. Squibb & Sons, Inc. | 10-(2'-hydroxy-3'-alkoxy-1,4,7-triscarboxymethyl-1,4,7,10- tetraazacyclododecanes |
US5679810A (en) * | 1990-01-19 | 1997-10-21 | Salutar, Inc. | Linear oligomeric polychelant compounds |
WO1992017215A1 (en) | 1990-03-28 | 1992-10-15 | Nycomed Salutar, Inc. | Contrast media |
GB9024208D0 (en) * | 1990-11-07 | 1990-12-19 | Salutar Inc | Compounds |
DE4035760A1 (en) * | 1990-11-08 | 1992-05-14 | Schering Ag | MONO-N-SUBSTITUTED 1,4,7,10-TETRAAZACYCLODODECAN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM |
CA2072934C (en) * | 1991-07-19 | 2007-08-28 | Karl William Aston | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
DE69224839T2 (en) * | 1991-07-19 | 1998-10-08 | Monsanto Co | Manganese complexes with nitrogen-containing macrocyclic ligands, effective as superoxide dismutase catalysts. |
WO1994004485A1 (en) * | 1992-08-19 | 1994-03-03 | Mallinckrodt Medical, Inc. | LIGANDS FOR Ga-68 PET HEART APPLICATIONS |
US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
WO1995014726A1 (en) * | 1993-11-26 | 1995-06-01 | The Dow Chemical Company | Process for preparing polyazamacrocycles |
JPH10500401A (en) * | 1994-04-22 | 1998-01-13 | モンサント カンパニー | Diagnostic image analysis method using metal complex |
EP0846003A1 (en) | 1995-08-17 | 1998-06-10 | Monsanto Company | Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands |
US5976498A (en) * | 1995-08-17 | 1999-11-02 | Neumann; William L. | Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands |
AU5871000A (en) | 1999-06-11 | 2001-01-02 | Paul G. Abrams | High dose radionuclide complexes for bone marrow suppression |
US7094885B2 (en) | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
FR2830253B1 (en) * | 2001-09-28 | 2005-02-04 | Air Liquide | NOVEL PROCESS FOR THE PREPARATION OF C-FUNCTIONALIZED NITROGEN MACROCYCLES AND NOVEL INTERMEDIATES OBTAINED |
FR2968999B1 (en) | 2010-12-20 | 2013-01-04 | Guerbet Sa | CHELATE NANOEMULSION FOR MRI |
CN107847617B (en) * | 2015-03-10 | 2021-08-31 | 爱默蕾大学 | Metal tricarbonyl complexes containing substituted iminodiacetic acid ligands and their use as radiotracers |
WO2017011517A1 (en) | 2015-07-16 | 2017-01-19 | Emory University | Bis-amines, compositions, and uses related to cxcr4 inhibition |
CN106588925B (en) * | 2016-12-05 | 2018-03-30 | 天津羲泽润科技有限公司 | It is a kind of to prepare the luxuriant method of the pyridine ring of 1,4,7,10 4 azepine 2,6 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO149961C (en) * | 1981-06-01 | 1984-07-25 | Borregaard Ind | PROCEDURE FOR THE PREPARATION OF N- (2-HYDROXYethyl) DERIVATIVES OF MACROCYCLIC POLYAMINES, CONTAINING MULTIPLE 1.4 NITROGEN ATOMS IN THE RING |
NL194579C (en) * | 1983-01-21 | 2002-08-05 | Schering Ag | Diagnostic. |
DE3316703A1 (en) * | 1983-05-04 | 1984-11-08 | Schering AG, 1000 Berlin und 4709 Bergkamen | ORAL CONTRAST AGENT FOR MRI MRI AND THE PRODUCTION THEREOF |
JPS60202869A (en) * | 1984-03-26 | 1985-10-14 | Ajinomoto Co Inc | Macrocyclic polyamine derivative and its use |
US4639365A (en) * | 1984-10-18 | 1987-01-27 | The Board Of Regents, The University Of Texas System | Gadolinium chelates as NMR contrast agents |
DE3772785D1 (en) * | 1986-01-23 | 1991-10-17 | Squibb & Sons Inc | 1-SUBSTITUTED-4,7,10-TRISCARBOXYMETHYL-1,4,7,10-TETRAAZACYCLODODECAN AND ANALOG. |
GB8603537D0 (en) * | 1986-02-13 | 1986-03-19 | Parker D | Conjugate compound |
DE3625417C2 (en) * | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecane derivatives |
GB8719041D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8719042D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
-
1987
- 1987-04-14 FR FR8705288A patent/FR2614020B1/en not_active Expired
-
1988
- 1988-04-12 DD DD88314659A patent/DD293113A5/en not_active IP Right Cessation
- 1988-04-12 ZA ZA882552A patent/ZA882552B/en unknown
- 1988-04-12 NO NO881567A patent/NO176839C/en unknown
- 1988-04-12 PT PT87216A patent/PT87216B/en not_active IP Right Cessation
- 1988-04-13 DK DK202788A patent/DK170946B1/en not_active IP Right Cessation
- 1988-04-13 EP EP88400895A patent/EP0287465B1/en not_active Expired - Lifetime
- 1988-04-13 FI FI881708A patent/FI93830C/en not_active IP Right Cessation
- 1988-04-13 IE IE111488A patent/IE62582B1/en not_active IP Right Cessation
- 1988-04-13 YU YU74288A patent/YU46691B/en unknown
- 1988-04-13 KR KR1019880004187A patent/KR880012572A/en not_active Application Discontinuation
- 1988-04-13 ES ES88400895T patent/ES2053779T3/en not_active Expired - Lifetime
- 1988-04-13 AT AT88400895T patent/ATE85052T1/en not_active IP Right Cessation
- 1988-04-13 JP JP63089189A patent/JP2675058B2/en not_active Expired - Lifetime
- 1988-04-13 DE DE8888400895T patent/DE3877799T2/en not_active Expired - Fee Related
- 1988-04-13 HU HU881897A patent/HU198501B/en not_active IP Right Cessation
- 1988-04-13 SI SI8810742A patent/SI8810742A/en unknown
- 1988-04-13 IL IL86059A patent/IL86059A/en not_active IP Right Cessation
- 1988-04-14 AU AU14611/88A patent/AU606146B2/en not_active Ceased
- 1988-04-14 CN CN88102139A patent/CN1022411C/en not_active Expired - Fee Related
-
1992
- 1992-09-26 HR HRP920514AA patent/HRP920514A2/en not_active Application Discontinuation
-
1993
- 1993-03-30 GR GR930400681T patent/GR3007495T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO176839B (en) | Ligands and methods for their preparation, metal complexes formed with these ligands, as well as diagnostic composition and X-ray contrast agent comprising the above metal complexes | |
US5417960A (en) | Nitrogen-containing cyclic ligands, metallic complexes formed by these ligands, diagnostic compositions containing these complexes and process for the preparation of the ligands | |
EP0391766B1 (en) | Macrocyclic nitrogen ligands, method of preparation, metal complexes formed by the ligands, diagnostic and therapeutic compositions containing them | |
KR102703312B1 (en) | Contrast agent | |
CZ282873B6 (en) | Process for preparing derivatives of n-beta-hydroxyalkyl-tri-n-carboxyalkyl-1,4,7,10-tetraazacyclododecane and n-beta-hydroxyalkyl-tri-n-carboxyalkyl-1,4,8,11-tetraazacyclotetradecane and their metal complexes | |
CZ295406B6 (en) | Process for the preparation of tetraazamacrocyclic compounds | |
NO177783B (en) | Heterocyclic polyamines | |
JP3471836B2 (en) | Method for producing mono-N-substituted tetraazacyclododecane derivative and -tetradecane derivative, and method for producing metal complex for diagnosis and treatment | |
CZ304573B6 (en) | Lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, process preparing these complexes and gadobutrol | |
US5705637A (en) | Polyazacycloalkane compounds | |
MX2007013113A (en) | Synthesis of cyclen derivatives. | |
EP0365412B1 (en) | Cyclic nitrogen-containing ligands, their metal complexes, diagnostic compositions containing these complexes and method of preparing the ligands | |
KR100614535B1 (en) | A Process for the Preparation of 1,4,7,10-Tetraazacyclododecane | |
EP0540975B1 (en) | Diethylenetriamine derivatives and their use for diagnostic and therapeutic purposes | |
DE69621787T2 (en) | POLYAZACYCLOALKANVERBINDUNGEN | |
EP4457228A1 (en) | Novel bispidine-based metal chelating ligands displaying good relaxivity | |
JPS6136270A (en) | Manufacture of 2_alkyl_4,5_dihydroxymethylimidazole | |
EP3386953B1 (en) | Contrast agents | |
NO334346B1 (en) | Chelating agents in the form of bifunctional tridentate pyrazole-containing ligands for RE and TC tricarbonyl complexes and their use, process for the preparation of radiolabelled biomolecules, and kits for carrying out the process | |
Doak et al. | 2-Hydroxy-4-aminobenzenephosphonic Acid, an Analog of p-Aminosalicylic Acid | |
JPH03112969A (en) | Producing intermediate of bifunctional chelate ligand and production thereof | |
CS217938B1 (en) | Method of preparation of the 1,3-oxazolidine-4-on | |
WO2004082721A1 (en) | Complexes of gd +3 gadolinium ions with derivatives of n-2- (2- (phenylamino) -2- oxoethyl) -n- (carboxymethyl) - glycine and method for obtaining these complexes |